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Abstract:
Progesterone is an ovarian steroid hormone which plays a very important part in the
regulation of pregnancy-related changes. Progesterone functions by binding to its
specific nuclear receptor, PR, which regulates defined genes in a ligand dependent
manner. The aim of my thesis is to explore and elucidate some of the important
mediators of progesterone action with regards to pregnancy-related mammary gland
development and also uterine development. Knockout mouse models and comparative
wild type mice were used in order to explore the expression patterns of specific genes
of interest. Quantitative PCR using cDNA derived from mammary gland tissue was
used to analyse the differences in gene expression of progesterone’s downstream
target molecules. Established target genes such as RANKL, Wnt4 and Amphiregulin,
TGF-β1, Sfrp2 and Mig6 were analysed to determine their mRNA expression levels
in the late stages of pregnancy where growth and proliferation is at its most intense.
Comparisons were then made between the mammary gland and the uterus, in order to
assess the tissue specificity of progesterone function. The results clearly indicate how
progesterone is able to mediate both proliferative and anti-proliferative signals to
ensure normal structural development within both the mammary gland and the uterus.
A novel target gene; BDNF; was shown to be strongly regulated by PR and was also
analysed in terms of the proliferative target genes to determine what functional role it
may have in the signalling pathways. The findings of this study will help to further
understand the intricacies of progesterone dependent signalling in both normal and
tumourigenic mammary gland development.
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1. Introduction
1.1. Mammary Gland Structure:
The mammary gland consists of two tissue compartments: the epithelium and
the stroma. The epithelium of the mature non-pregnant mouse resembles a
branching tree-like ductal structure that develops during puberty and milkproducing alveolar cells which develop during pregnancy (Molyneux et al,
2007; Hennighausen et al, 2001). The primary ducts branch into decreasingly
smaller secondary and tertiary ducts. These ductal branches of the mammary
gland are encased in myoepithelial cells on the exterior and lined with ductal
luminal cells along its length (Buono et al, 2006). The ductal branches terminate
in lobules; which are composed of alveoli, which in turn consist of secretory
epithelial cells that undergo functional differentiation in pregnancy
(Hennighausen et al, 2001). The alveoli have a more open network of
myoepithelium than the characteristic continuous layer of the ducts. These
alveolar cells also contain smooth muscle actin and contract in response to
oxytocin stimulation, which results in milk release (Hennighausen et al, 2001).
A basement membrane separates this extensive system of ducts and alveoli from
the surrounding fatty stromal matrix in which they are embedded (Molyneux et
al, 2007; Hennighausen et al, 2005). The stroma also known as the mammary
fat pad consists mainly of adipocytes but fibroblasts, blood vessels and neurons
are also present (Hennighausen et al, 2005).
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The cellular structure of the mammary gland is dependent on distinct cell
lineages. It has been proposed that cells forming the epithelial compartment of
the mammary gland are derived from mammary stem cells which have the
capacity to self renew and give rise to committed epithelial precursor cells
(EPCs). The progeny of the EPCs are then restricted to either a ductal or
alveolar fate (Hennighausen et al, 2005). The ductal precursor cells form basal
cells and luminal cells, the two cell types that constitute ducts. During
pregnancy, alveoli are generated from alveolar precursors which give rise to
basal and luminal cells, the differentiated milk-producing cells. The presence of
stem cells is the basis of the profound capacity for alveolar renewal in each
subsequent pregnancy (Hennighausen et al, 2005).

1.2. Mammary Gland Development:

1
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Fig 1.1: A diagram which depicts the stereotypical morphological changes that occur during
murine postnatal mammary gland development, the mammary gland cycle of development
begins with pregnancy and concludes with the completion of the involution process
(Fernandez-Valdivia et al, 2005).
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Development of the mammary gland occurs in defined stages that are connected
to sexual development and reproduction (fig.1.1). These stages are essentially
conserved between rodents and humans and are referred to as embryonic,
prepubertal, pubertal, pregnancy, lactation and involution (Hennighausen et al,
2001).

1.2.(i)Embryonic and Prepubertal Mammary Gland
Development:
The initial stages of mammary development in the embryo occur independently
of steroid hormone regulation. In the mouse embryo, there are five pairs of
glands which develop along a line that that runs slightly ventral to the limb
buds, whereas only one pair develops in the thoracic region in humans
(Hennighausen et al, 2005). In mice, five ectodermal placodes appear between
embryonic days 10 and 11. The placodes form buds which slowly increase in
size up to embryonic day 15. Cell proliferation intensifies at the tip of the bud
and leads to the formation of a primary sprout which grows out toward the
prospective mammary fat pad. Continued proliferation and branching leads to
the formation of a small ductal tree at birth (Hennighausen et al, 2001). This
primitive rudimentary gland grows just enough to keep up with normal body
growth until pubertal stage of growth can begin (Hennighausen et al, 2005).
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1.2.(ii) Pubertal Mammary Gland Development:
The bulk of mammary gland development occurs postnatally in two distinct
growth phases that are initiated at the onset of puberty and pregnancy
respectively (Conneely et al, 2003). During puberty, cyclical production of
ovarian estrogen and progesterone accelerates ductal outgrowth and branching
(Hennighausen et al, 2005). Growing epithelial ducts in pubescent animals have
conspicuous club-shaped structures at their distal ends which are known as
terminal end buds (TEBs) (Conneely et al, 2003). The TEBs consist of two
morphologically distinct cell types, an inner layer of body cells and an outer
layer of cap cells (fig.1.2). It is likely that there is stem cell activity within the
cap cells (Molyneux et al, 2007). Under the regulation of estrogen and other
locally acting growth factors; these cells divide at a high rate and proliferate to
promote ductal elongation and dichotomous secondary side branching
(Conneely et al, 2003).
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Fig 1.2. The ducts of the developing mammary gland are established as the terminal end buds (TEBs). The
TEBs move through the mammary fat pad, they consist of an inner luminal epithelial cell layer and an outer
myoepithelial cell layer. It is thought that the cap cells at the tip of the TEB generate transit cells of a
myoepithelial lineage on the outer side of the TEB and generate transit cells — known as 'body cells' — of a
luminal epithelial lineage to form the central TEB mass. The ductal lumen is formed as central body cells
apoptose and outer cells differentiate into luminal epithelial cells. Extracellular-matrix enzymes degrade the
stroma in front of the TEB to enable it to move through the fat pad, but it is unclear how the structures actually
'move' through the gland. It might simply be that progressive cell division building up cell bulk at the front of
the mass of body cells, coupled with progressive apoptosis degrading cell bulk at the back of the body cell
mass, creates the illusion of forward movement (Smalley et al, 2003).

The ducts grow into the mammary fat pad, branching at regular intervals to
create a network of primary and secondary ducts. During lactation, these
primary and secondary ducts form continuous channels for the transport of milk
from the secretory alveoli to the nipple (Molyneux et al, 2007). Once the fat pad
has been filled with glandular tissue, the TEBs will regress, and are then
converted to terminal ducts (Conneely et al, 2003; Molyneux et al, 2007).
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At adulthood, the virgin gland becomes relatively quiescent with the exception
of small side-branches which form and disappear on primary and secondary
ducts as a result of the cyclic rise of ovarian steroids during the estrous cycle
(Molyneux et al, 2007, Hennighausen et al, 2005). Precursors of the secretory
alveolar structures may also appear and regress during the estrous cycle
(Molyneux et al, 2007).

1.2.(iii) Pregnancy-Associated Mammary Gland Development:
During pregnancy, a surge of hormones results in major structural changes in
the mammary gland (Molyneux et al, 2007). Exposure to progesterone and
prolactin results in extensive epithelial proliferation, increased side branching of
both secondary and tertiary ducts and differentiation of milk-filled alveolar
lobules that uniformly fill the interductal spaces by late pregnancy (Conneely et
al, 2003). The combined action of both progesterone and prolactin dependent
signalling pathways is essential to achieving the proper pregnancy-associated
ductal and alveolar morphogenesis of the mammary gland (Conneely et al,
2003). In humans, the alveoli are localised in clusters which resemble bunches
of grapes and are called Terminal Ductal Alveolar Units (TDLUs) (Molyneux et
al, 2007). Nearing parturition, alveolar tight junctions close and milk and
colostrum proteins move into the alveolar lumen in preparation for active milk
secretion (Oakes et al, 2006). During suckling, milk is expelled by contractile
myoepithelial cells which form a basketlike network to the nipple (Molyneux et
al, 2007). At the end of lactation, the loss of suckling stimuli and the pressure

6

build-up on cessation of milk removal initiates a remodelling programme called
involution. This causes massive cell death; it causes the collapse of the alveoli
and the remodelling of the epithelial compartment to restore a simple duct
structure which resembles the prepregnant mammary gland. A new
developmental cycle of alveolar expansion, maturation, lactation and involution
is initiated with the next pregnancy (Hennighausen et al, 2005).

1.3. The Ovarian Steroid Hormones:
Hormones are signalling molecules which travel through the bloodstream and
interact with cells in a variety of target tissues via specific receptors. The
ovarian steroid hormones are derived from a cholesterol precursor and contain
four rings of 17-carbon atoms (Fig 1.3) (Kleinsmith et al, 2007). The side chains
attached to the carbon rings enable the hormone molecules to confer specificity
for appropriate receptors.
Fig 1.3: The chemical
structures of the two
ovarian steroid hormones;
estradiol (E) and
progesterone (P)
Estradiol

Progesterone

1.3.(i): The Steroid Hormone Receptors; ER and PR:
This project focuses on two ovarian steroid hormones; estrogen (E) and
progesterone (P), because of their specific and overlapping interactions in both
the breast and the uterus. Steroid hormones mediate their cellular effects
7

through their specific steroid receptors. Estrogen or estrogen-related molecules
bind specifically to the estrogen receptor (ER) whilst progesterone or
progesterone-related molecules bind specifically to the progesterone receptor
(PR). Both ER and PR are members of the nuclear receptor superfamily and
therefore they share the structural homology and the key functional domains
that are common to this group (Lee et al, 2006). ER and PR have three major
functional domains; the ligand-binding domain, the DNA binding domain, and
an activation domain. The ligand-binding domain confers specificity to the
receptor for a particular ligand that regulates its transcriptional activation (Lee
et al, 2006). The DNA-binding domain determines which DNA sequences the
receptor will recognise while the activation domain links transcriptional activity
of the receptors to the core transcriptional complexes (Lee et al, 2006).
Both ER and PR are intracellular receptors therefore in order for activation to
occur, a specific hormone ligand must enter the cell. Estrogen and progesterone
are both small, lipophilic, hydrophobic molecules which can easily diffuse
through the phospholipid bilayer of the cell membrane and into the cytoplasm.
Once in the cytoplasm, the ligand binds to and induces a conformational change
in the specific receptor, the ligand-receptor complex is then activated and can
then translocate to the nucleus. In the nucleus, the ligand-receptor complex
interacts with the genome and binds to particular response elements which are
situated near the target genes. Progesterone-bound PR seems to bind as a
homodimer to cis-acting progesterone response elements that are usually present
in the 5’ flanking regions of the specific genes (Lee et al, 2006). This ligand
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dependent signalling enables the ligand-receptor complex to interact with the
cell genome to activate or to silence the transcription of downstream effector
pathways (Lee et al, 2006). It is the induction or suppression of these pathways
by the ovarian steroid hormones that produce the physiological responses
observed in the breast and the uterus (Fig 1.4).
In the absence of any ligand-binding, the steroid receptors remain
transcriptionally inactive and are unable to interact and influence the DNA.
Under such circumstances, PR is known to associate with a large complex of
chaperone proteins including heat shock proteins in the cytoplasm. Only
specific ligand binding can release PR from the chaperone complex so that it
can undergo the conformational change which will enable it to translocate to the
nucleus (Lee et al, 2006).

Fig 1.4: Schematic diagram depicting the ligand dependent signalling of steroid hormone receptors
(NR) within the cell once they are bound by the steroid hormone in the cytoplasm. In the absence of
steroid hormone, the steroid receptor is in an inactive state and is bound to a complex of chaperone
proteins such as heat shock protein 90 (HSP) in the cytoplasm. The steroid hormone interacts with
the receptor and changes its conformation which dissociates it from the chaperone complex so
activation can occur. The newly formed ligand-receptor complex dimerizes and translocates to the
nucleus where it recruits other coactivator proteins and interacts with cells genome to regulate
transcription (http://en.wikipedia.org/wiki/Nuclear_receptor - 3rd September 2008).
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1.3.(ii) The Estrogen Receptor Isoforms; ERα and ERβ:
Estrogen and estrogen-related molecules can bind to two distinct receptors; ERα
and ERβ, which are encoded by two separate genes. ERα and ERβ function as
transcription factors when bound to the steroid hormone. PR is a known
transcriptional target of the ERs in the reproductive tissues, including the
mammary gland (Hennighausen et al, 2001; Conneely et al, 2003).
In puberty, ductal branching within the mammary gland requires growth
hormone and also estrogen; which signals predominantly through ERα. A
deletion of ERβ has no adverse effects on ductal and alveolar development,
whereas both stromal and epithelial ERα seem to be required for normal ductal
elongation and outgrowth during puberty (Hennighausen et al, 2005; Conneely
et al, 2003).

1.3.(iii) The Progesterone Receptor Isoforms; PR-A and PR-B:
Progesterone (P) has been referred to as the ‘hormone of pregnancy’ as its
hormonal effects are seen to dominate development during pregnancy.
There are two distinct PR isoforms; PR-A and PR-B (Lessey et al, 1983). Both
isoforms arise from alternative transcription start sites in the single PR gene
(Molyneux et al, 2007). The isoforms are transcribed at two distinct promoters
and translated at two alternative AUG signals (Conneely et al, 2001). PR-B
contains a short additional stretch of amino acids, termed the B-upstream
sequence (BUS) which is located at the N-terminus of the receptor. The BUS
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domain contains the transactivation function (AF-3) which is not present in the
PR-A isoform (Fernandez-Valdivia et al, 2005).

Fig 1.5: Diagram depicting two specific PR isoforms; PR-A and PR-B. There is a third PR isoform; PRC but there is currently little information on its function. PR-B has the additional BUS domain attached to
its N-terminal domain.

Both the A and B protein of PR are capable of binding P, dimerizing and
interacting with P responsive elements and the transcriptional machinery to
regulate gene expression. When expressed in equimolar ratios in cells, the A
and B proteins can dimerize and bind DNA as three species: A:A or B:B
homodimers or A:B heterodimers (Conneely et al, 2001). It is generally thought
that PR-A and PR-B are functionally different, that they regulate different
physiological target genes and that they have different transactivation
capabilities in different target tissues. Results have previously shown that if
agonist bound PR-A is inactive, then it can act as a dominant repressor of PR-B
activity; this repressor capability appears to be a selective property of the PR-A
protein and has been shown to extend to other steroid receptors through
competition for common limiting coactivators (Conneely et al, 2001). PR-A
and PR-B also respond differently to progestin antagonists, PR-A is rendered
inactive whilst PR-B is converted to a strongly active transcription factor
(Conneely et al, 2001).
11

1.3.(iv) The PRKO Mouse Model:
As a way of directly delineating progesterone’s involvement in general
reproductive endocrinology, a progesterone receptor knockout (PRKO) mouse
was generated in which both isoforms of PR were functionally ablated through
gene targeting approaches (Ismail et al, 2003). Abrogation of the P signal
resulted in an overt female infertility phenotype in which normal ovarian-,
uterine- and behavioural-functions were severely compromised (Ismail et al,
2003). Despite these reproductive phenotypes, the PRKO mammary epithelium
responded to the pubertal rise in serum levels of E to generate a normal ductal
architecture almost indistinguishable from that of the wild-type (Ismail et al,
2003). The normal development of the PRKO pubertal gland is in stark contrast
to the estrogen receptor-α knockout (ERKO) pubertal gland which exhibited
ductal outgrowth defects.
In PRKO mice, there is no development of tertiary ductal side branching and no
differentiation of the epithelial cells which confirms a specific role for P in
pregnancy associated mammary gland development (Conneely et al,
unpublished). In order to learn more about the actions of P in the mammary
gland during pregnancy, isolated PRKO mammary epithelial cells (MECs) were
transplanted into the cleared mammary fat pad of a wild-type nulliparous host
(Ismail et al, 2003). Experimental techniques such as these were developed in
order to circumvent the block to pregnancy presented by the PRKO animal
(Ismail et al, 2003).
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1.3.(v) Progesterone’s Role in the Pregnant Mammary Gland:
Progesterone action in the mammary gland strongly induces increased tertiary
side-branching and along with prolactin instigates the proliferative phase of
alveolar morphogenesis for milk production. Administration of E plus P to agematched wild-type virgins and PRKOs associated the absence of progesterone
with a block in hormone-induced cellular proliferation (Ismail et al, 2003).
During pregnancy, there is massive tissue remodelling within the mammary
gland. Cell differentiation becomes dominant from mid-pregnancy as the gland
moves into the secretory initiation phase. The developing alveoli cleave and the
alveolar cells become polarised and form a sphere-like single layer of epithelial
cells that envelopes a circular lumen, connected to the ductal network via a
single small duct (Oakes et al, 2006). Tissue localisation and epithelial
recombination experiments demonstrate that progesterone in the mammary
epithelium, not the stroma, was essential for epithelial cell proliferation and
lobuloalveolar development, although stromal PR may play a role in tertiary
branching (Oakes et al, 2006; Sternlicht et al, 2006). PR-expressing cells are
evenly spaced in the ducts of young mice but their distribution becomes mosaic
in mature virgin mice and during early pregnancy. In early pregnancy, PRpositive MECs are found closely apposed to proliferating epithelial cells
(Hennighausen et al, 2005). This segregation of PR-positive cells from
proliferating cells is a conserved feature in normal rodent and human mammary
tissue. An expression pattern such as this suggests that the regulation of
epithelial cell proliferation by P may occur through a paracrine mechanism. PRs
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residing in non-proliferating cells may induce expression of a proliferative
signal that can promote proliferation of neighbouring receptor negative cells
(Conneely et al, unpublished). PR has been identified as a transcriptional target
of ERα in reproductive tissues and the mammary gland, however absence of
ERα does not result in the loss of PR expression in mammary epithelium. If
ERα null mammary cells are supplemented with P and prolactin, they respond
by inducing lateral side-branching and lobular alveolar differentiation
(Conneely et al, unpublished).

1.4. A Role for Progesterone in Mammary
Tumourigenesis:
The pivotal role played by the progesterone proliferative signal in normal
mammary gland development raised the possibility of whether progesterone
may also affect mammary gland tumourigenesis (Ismail et al, 2003). Ablation of
PR expression in PRKO mice resulted in a significantly reduced incidence of
mammary tumour growth in response to carcinogen challenge relative to the
wild-type littermates underscoring a specific role for PR as essential regulators
of intracellular signalling pathways that are essential for the initiation of murine
mammary tumours induced by carcinogens (Conneely et al, 2003). Also in
many human breast tumours, the majority of ER and PR positive cells undergo
proliferation. This observation suggests a switch in steroid dependent regulation
from a paracrine to autocrine mechanism as populations of proliferating MECs
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which are positive for ER and PR emerge in response to carcinogen challenge
(Conneely et al, 2003).
The following sections; 1.4(i) to 1.4(v), summarise the research efforts which
have been made in recent years to link progesterone with breast related
tumourigenesis. Research such as this has encouraged the work in this thesis
and is essential if new and more effective treatments are to be made available
for the many women who develop breast cancer around the world.

1.4.(i) Reproductive History-Associated Risk:
Reproductive history is a consistent risk factor for human breast cancer. Whilst
an early first pregnancy has a strong protective factor against breast cancer, the
highest incidence of breast cancer still occurs in the premenopausal
reproductive years (Conneely et al, 2003). It is at this biological time-point that
the MECs are most reliant on the ovarian steroid hormones for proliferation
therefore it is important to investigate the relationship between hormone
dependent MEC proliferation and the acquisition of cancer causing genetic
mutations. The average woman undergoes hundreds of cycles of breast cell
division and cell death repeated over a span of roughly forty years, from puberty
to menopause (Fig 1.6).
Although the steroid hormones do not seem to directly cause the DNA
mutations, proliferation of normal cells from exposure to these hormones
creates a vulnerability to spontaneous somatic DNA mutations, some of which
may represent a first step on the pathway to cancer.
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Fig 1.6: A chart depicting the
hormonal changes associated
with the human female
28 day menstrual cycle.
Estrogen spikes just before
ovulation whilst progesterone
spikes in the middle of the
luteal phase. However, in the
absence of pregnancy,
progesterone levels drop off
towards the end of the cycle
(http://upload.wikimedia.org/
wikipedia/commons/thumb/f/f
0/MenstrualCycle.png/300pxMenstrualCycle.png - 2nd
August 2008).

Alternatively if one or more breast cells possess a DNA mutation that increases
the risk of developing cancer, then these mutant cells will proliferate along with
the normal breast cells in response to the hormone stimulation and also increase
the risk of breast cancer development (Kleinsmith et al, 2007).
Research with progesterone receptor knockout (PRKO) mouse models has
indicated that progesterone is specifically involved in inducing epithelial
proliferation. The luminal compartment of mammary epithelium has been
shown to be the target of this progesterone-induced proliferation, this
compartment also happens to be the site of mammary epithelial tumourigenesis

1.4.(ii) Progesterone in mouse mammary carcinogenesis
In 1999, Lydon et al studied the functional relevance of progesterone-initiated
intracellular signalling in mammary gland tumourigenesis by using the PRKO
mouse model in the context of an established carcinogen-induced mammary
tumourigenesis system. At five weeks, female wild type (WT) and PRKO mice
received pituitary isografts in order to induce a high incidence of mammary
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tumours with a short latency period. At eight weeks, the mice were administered
1 mg weekly of the carcinogen 7,12-dimethylbenz(a)anthracene (DMBA) for
three consecutive weeks. The control group, who received no pituitary isografts,
were administered 1 mg weekly of DMBA for six consecutive weeks. In
DMBA-treated pituitary-isografted mice, a reduction was observed in the
mammary tumour incidence in PRKO mice as compared with isogenic WT
mice. Mammary tumours developed in 60% of the WT mice but only 15% of
the PRKO mice by 44 weeks after DMBA treatment. With no pituitary isograft,
mammary tumours were observed in 20% of the WT mice and 20% of the
PRKO mice up to 47 weeks. When the carcinogen was administered, the
proliferative index of the pituitary-stimulated WT mammary gland was fourfold higher than similarly treated PRKO glands. This study indicates a specific
role of the PR as a mediator for intracellular signalling pathways that are
essential for the initiation of the majority of murine mammary tumours induced
by DMBA. The data strongly supports a role of progesterone in a murine model
of carcinogen-induced mammary gland tumourigenesis (Lydon et al, 1999).

1.4.(iii) The Women’s Health Initiative (WHI) HRT Study
One high profile study in 2002 proposed a link between progesterone and breast
cancer in menopausal women undergoing hormone replacement therapy (HRT)
(Roussouw et al, 2002). HRT is aimed at women who have passed through
menopause and as a result produce significantly reduced amounts of estrogen.
The lack of estrogen in these women is linked to several health problems.
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Estrogen has positive effects on blood vessels and on bones therefore after
menopause, women are at increased risk for heart disease and osteoporosis. To
counteract such potential problems, some postmenopausal women undergo
hormone replacement therapy (HRT) and take hormone pills containing
estrogen to strengthen bones and help control other menopausal symptoms.
Unfortunately there are some serious risks associated with HRT; the potentially
harmful proliferative effects of estrogen have been well established, namely an
increased risk for invasive breast cancer and for uterine cancer in women with
an intact uterus. Estrogen blockades have been developed as both a prophylactic
tool to prevent cancer development and as chemotherapy in early stages of
breast cancer (Roussouw et al, 2002). Studies which were done in the 1980’s
suggested that adding progesterone to estrogen could offer a protection against
the harmful proliferative effects of estrogen on the uterus. HRT which
combined both estrogen and progesterone became very common however, only
women who had an intact uterus benefited from the addition of progesterone
whilst those women who had undergone a hysterectomy continued to receive
HRT with estrogen alone (Kleinsmith et al, 2007).
In July 2002, the National Institutes of Health (NIH) halted a large, in-progress
study examining the effects of a widely used type of HRT medication called
Prempro®, which combines the hormones estrogen and progestin. The study
was scheduled to run until 2005 and was to determine whether estrogen plus
progestin could prevent heart disease and hip fractures in women between ages
50 and 79 with an intact uterus. Preliminary studies found a 26 percent increase
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in breast cancer in women receiving the hormones compared with women
receiving a placebo. Those figures represent the relative incidence of the
findings however when the data is examined in terms of relative risk for the
individual woman, the results and the associated risks appear far less sinister
(Roussouw et al, 2002).
The WHI results suggest that during one year, among 10,000 postmenopausal
women with a uterus [as opposed to those who had a hysterectomy] who are
taking estrogen plus progestin, eight more will have invasive breast cancer, than
will a similar group of 10,000 women not taking these hormones. This is a
relatively small annual increase in risk for an individual woman. The WHI study
did however spur further investigations into the nature of PR and the potential
threat that it may pose to normal mammary gland development (Jovanovic
Poole et al, 2006).

1.4.(iv) Hormone Dependence in Premalignant Mammary
Progression
This marked dependence on progesterone-mediated signalling for
tumourigenesis was examined in another study in 2003 by Medina et al. They
looked at a model of mouse mammary tumourigenesis; BALB/c p53-null
mammary epithelium. This mouse model has a deletion of the tumour
suppressor gene p53 which results in enhanced tumourigenic risk. The model
progresses through ductal hyperplasia and then ductal carcinoma in situ before
becoming invasive breast cancer. The p53-null mammary cells exhibit the same
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properties of hormone dependence as p53 wild-type cells but they are highly
sensitive to the tumour-promoting effects of the ovarian hormones. The study
examined the effect of chronic administration of progesterone on the
tumourigenic potential of p53-null mammary epithelial cells over a 14 month
period. Mice with p53 wild-type mammary epithelium were not evaluated
because previous experiments had shown that chronic hormone stimulation did
not convey a tumourigenic stimulus over these time periods.
The importance of normal signalling of progesterone was demonstrated by
removing PR function in the p53-null epithelial cell. The group cross-bred p53null mice with PRKO mice to generate p53-/-,PR-/- mammary ducts. Mammary
tumourigenesis in hormone-stimulated p53-null epithelial cells was markedly
reduced in the absence of progesterone signalling from 84% to 32%. The
removal of progesterone-stimulated proliferation in the mammary gland
decreased the number of tumours by almost two-thirds in the p53-null mice thus
suggesting that progesterone has significant tumourigenic potential under such
circumstances.

1.4.(v) Prevention of BRCA1-Mediated Mammary
Tumourigenesis in Mice by a Progesterone Antagonist
In 2006, a paper by Poole et al demonstrated that a progesterone antagonist
mifepristone (RU486) was able to prevent mammary tumourigenesis in a
BRCA1/p53 conditional knockout mouse model. This was the first paper to
produce a very strong and substantial data set for the critical role of PR function
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in mammary carcinogenesis. BRCA1 (breast cancer 1) is a human gene that
belongs to a class of genes known as tumour suppressors, which maintains
genomic integrity to prevent uncontrolled proliferation. The BRCA1 protein is
implicated in DNA damage repair, ubiquitination, cell cycle checkpoint control
and transcriptional regulation. Mutations in the gene have been implicated in a
number of hereditary cancers, namely breast, ovarian and prostate.
The specific suppression of breast and ovarian carcinogenesis by the BRCA1
tumour suppressor has been attributed to its regulation of ERα and the two PR
isoforms. BRCA1 interacts with ER and PRs directly and modulates liganddependent and ligand–independent transcription. The study by Jovanovic Poole
et al, attempted to address the specific roles of ER and PRs in BRCA1-mediated
tumourigenesis by studying a BRCA1/p53 conditional mammary gland
knockout mouse model and also a p53 mammary gland knockout mouse model.
Inactivation of both BRCA1 and p53 genes mimics the majority of human
BRCA1-associated tumours, which also harbour p53 mutations. The mammary
gland morphology of the mature, nulliparous BRCA1/p53 knockout model was
similar to that of a wild-type pregnant mouse suggesting that proliferation of
mammary epithelial cells (MECs) was altered. Proliferation of the MECs is
regulated by the ovarian hormones. MEC proliferation was measured by 5bromo-2-deoxyuridine (BrdU) staining and showed a five fold increase in
proliferation in the BRCA1/p53 knockout compared to wild-type mice. The
BrdU staining also showed that the paracrine action of PR was maintained in at
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least most cases of the hyperplastic BRCA1/p53 knockouts (Jovanovic Poole et
al, 2006).
This study also evaluated PR protein expression and demonstrated elevated
expression of PR-A in BRCA1/p53 conditional knockout mammary glands.
Overexpression of the short isoform, PR-A has been associated with abnormal
mammary gland development and ductal hyperplasia. The results suggest a
correlation between BRCA1 deficiency and PR accumulation.
Since progesterone is a potent mitogen for BRCA1/p53 MECs, the group tested
whether a blockade of PR activity by a progesterone antagonist could prevent or
delay mammary carcinogenesis in the BRCA1/p53 conditional knockout mouse.
Mice were treated with a placebo pellet or with a pellet containing mifepristone
(RU 486). The median tumour latency established for the BRCA1/p53 knockout
mice was 6.6 months with complete penetrance; however no palpable tumours
were detected in the mifepristone-treated mice at 12 months of age, thus
producing a 100% reduction in mammary carcinogenesis at that particular time
point. Five weeks of mifepristone treatment substantially reduced branching and
suppressed alveolargenesis in the mammary glands of BRCA1/p53 knockout
mice.
This study is very significant as it presents strong evidence that PR function is
critical for BRCA1-mediated mammary carcinogenesis and that antiprogesterone
treatment can prevent or delay mammary carcinogenesis in the BRCA1/p53
conditional knockout mice. Up to now, the therapeutic options for women with
BRCA1 mutations were very limited with a bilateral mastectomy the being the
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most common method of both treatment and prevention, however the results of
this creates an opportunity to investigate the use of antiprogesterones as a
potential chemopreventive strategy and offer hope for the many women who
carry a BRCA1 mutation (Jovanovic-Poole et al, 2006).
This thesis and its investigations of progesterone-mediated signalling is heavily
weighted on studies such as those discussed in section 1.4 because of the clear
associations they have made between progesterone and tumourigenesis.

1.5. Investigation of Signalling Mechanisms in
Mammary Gland Development:
Although, significant progress has been made over the last ten years towards
understanding the contribution of P to the proliferation and differentiation of the
normal mammary gland, the signalling mechanisms that mediate these Pdependent responses remain poorly understood (Conneely et al, 2001). This
section highlights a number of important investigations which were
implemented in order to explore, identify and elucidate the downstream targets
of P-regulated pathways in this thesis. With better knowledge of its functional
mediators, progress can be made to better understand how and where a
signalling pattern can become corrupted and cause abnormal or malignant
mammary gland development.
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1.5.(i) Cre/loxP Transgenic Mouse Models
Transgenic mouse models were used heavily in this thesis to generate
experimental data. The extensive homology between the murine and the human
form ultimately make transgenic animal studies an extremely worthwhile
research tools. In this instance, it was specifically PRKO mice which were
generated. The Cre/lox targeting approach was used to generate these valuable
PRKO mouse models.
Cre recombinase is an enzyme derived from the bacteriophage P1 that
specifically recognizes loxP sites. Cre has been shown to effectively mediate the
excision of DNA located between loxP sites by binding to each of the two
palindromic halves of the loxP sites (Franco et al, 2008). After the excision
event, the DNA ends recombine leaving a single loxP site in place of the
intervening sequence.
To use this system in the mouse, the Cre recombinase needs to be expressed at a
sufficiently high level either as a transgene or a ‘knock-in’ approach. An
additional mouse is needed in which the gene of interest is flanked by loxP sites
generating a floxed mouse. The resulting Cre mouse can then be crossed to the
floxed mouse to generate a mutant mouse in which a gene can be ablated or
overexpressed (Fig 1.7).
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Fig 1.7: A schematic diagram illustrating the gene targeting technique Cre/lox. Mice with
the Cre protein expressing in a specific cell type (eg MECs) are bred with mice that contain a
target gene (eg PR) surrounded by loxP sites. When the mice are bred, the cells carrying Cre
will cause the specific cells to lose the floxed target gene and thus produce conditional
knockout models of that specific knockout gene. (http://www.scq.ubc.ca/targeting-your-dnawith-the-crelox-system/)

The manipulation of the gene of interest will be determined by the
spatiotemporal expression of the Cre recombinase allowing for conditional
alteration of the gene of interest (Franco et al, 2008).
For this thesis, MMTV/Cre mice were cross bred with mice in which the PR
gene was floxed thus producing mutant mice in which the PR gene had been
100% ablated in the mammary gland. MMTV-Cre mice are a transgenic strain
of mice in which the P1 Cre recombinase is under the transcriptional control of
the mouse mammary tumour virus (MMTV) promoter/enhancer. The
MMTV/Cre transgene has high levels of recombination in the virgin and
lactating mammary gland with specificity for the luminal mammary epithelial
cell compartment. This strain was deemed highly appropriate as the PR gene
could be deleted specifically in the virgin and lactating mammary gland.
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1.5.(ii) DNA Microarray Technology
An Affymetrix DNA microarray was carried out prior to the commencement of
this thesis (Fig 1.8). The microarray technology used DNA extracted from the
mammary gland tissues of the PRKO transgenic mouse models. The DNA
microarray analysed the differential expression of several hundred genes in a
wild type mouse and concurrently compared these wild-type expression levels
to the expression of the same genes in a PRKO mouse model which was
conditional for the murine mammary gland.
In this instance, the primary intentions of the microarray were to observe the
regulation of the mouse genome in response to progesterone in pregnancy
associated mammary gland development. The mammary glands of both the
wild-type and PRKO mouse models were manipulated into a full-term pregnant
state by treating both sets of mice with low doses of estrogen and progesterone
over a three week period. It was important to control and standardise the amount
of administered exogenous ovarian hormone circulating within the mice
therefore all mice underwent an ovariectomy to ensure that no endogenous
hormone was being produced which could potentially interfere with the results.
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Fig 1.8: An example of a heat map
from the Affymetrix GeneChip®
Mouse Genome Array. Expression
values were visualised as colour maps
where the log of the expression
intensity values for each
progesterone-treatment group were
first centred on the mean values of the
corresponding vehicle control (WT).
In this array, the wild-type genes were
the control and were compared to
three different forms of the
conditional progesterone knockout
mouse model; PRKO, PRAKO and
PRBKO. Green signifies
downregulation whilst red signifies
upregulation of the target gene
(Conneely et al, unpublished data).

The results of this microarray essentially formed the basis for the investigations
undertaken by this thesis. The microarray heat map produced some predicted
results for the commonly documented and well established downstream target
genes of P however it also showed strong PR-regulation of some unexpected
mammary gland targets (Fig 1.9). The intention of this thesis was to examine
some of these well known genes and assess what role, if any, that they may have
in mediating the structural and functional changes that occur in the mammary
gland during pregnancy, i.e. tissue remodelling and alveolar differentiation. In
this thesis, the role of lesser known targets genes are also investigated in the
same mouse models to elucidate what kind of role they may be playing in
development at this specific time point.
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Fig 1.9: An introductory diagram of target genes that are analysed as potential mediators of P
signalling in this thesis. These targets were chosen on the basis of their expression profiles in the DNA
microarray which was carried out prior to this work. RANKL, Wnt4, Amphiregulin and Elf5 are
thought to have a proliferative effect on the mammary gland development whilst TGF-β1 and TGF-β2,
Mig6 and Sfrp2 are thought to be anti-proliferative. BDNF was also identified on the microarray as
being strongly regulated by P yet little is known about its role in mammary gland development.

1.5.(iii) Validation of Targets via quantitative PCR technology
The results obtained from a DNA microarray help identify potential mediators
of the progesterone signalling pathways however, it is common with an
microarray to get a significant number of ‘false hits’ therefore it is important
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that all of the genes which appear to be regulated by progesterone on the heat
map are in fact confirmed as bone fide targets of PR action using qPCR
technology. In the case of the mammary gland, priority is given to factors that
are known to promote proliferation and also to those factors which are known
secreted mediators as they in particular may have a role in the paracrine action
of PR in the mammary epithelial cells. Some genes which appear to be of
particular interest to the lab may merit further research by the lab and it is at this
point that the generation of specific conditional knock out mouse models can be
addressed.

1.6. Mediators of Progesterone Action in the
Mammary Gland:
1.6.(i): Prolactin
Prolactin expression is largely responsible for the production of milk during
lactation in the mammary gland. Whilst the hormone itself is not a direct
mediator of P, the prolactin receptor has been shown to be upregulated by P
(Oakes et al, 2006). Nevertheless, P and prolactin demonstrate a strong cofunctional relationship as they work together to prepare the mammary gland
during pregnancy. Massive tissue remodelling occurs within the mammary
gland during pregnancy, resulting in the formation of the lobuloalveoli that are
capable of milk secretion. It is important to emphasise that the formation of
these alveoli is highly dependent on the synergy between prolactin and P (Oakes
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et al, 2006). Pituitary prolactin stimulates ovarian P enabling P to maintain its
required levels during early pregnancy. In addition, upregulation of P
expression by prolactin and prolactin receptor expression by P suggests that
these hormones interact in a synergistic manner to control alveolar development
(Oakes et al, 2006). P and prolactin signalling pathways have many similarities
in their mediated effects during early pregnancy. Many of the target genes that
are of interest to this study have shown evidence of prolactin regulation as well
as P regulation which suggests cooperation and a possible convergence between
the two hormonal pathways.

The Proliferative Effectors of Progesterone Signalling:
1.6.(iii) RANKL:
As previously mentioned, PR positive cells can act on their neighbouring PR
negative cells in a paracrine fashion. Grafts of PRKO epithelium or stroma in
combination with PR WT stroma or epithelium demonstrated that mammary
epithelial cells can give rise to alveoli when placed in close vicinity to PR WT
epithelial cells, indicating that progesterone does not need to act directly on the
alveolar cells and instead can orchestrate the morphogenetic and proliferative
events of alveolargenesis by affecting nearby cells in the mammary epithelium
(Brisken et al, 1998). A secreted protein known as RANKL (receptor activator
of nuclear factor ĸB – ligand) is known to be regulated by PR and is one of
these paracrine mediators of alveolar proliferation and survival (Fig 1.10)
(Kleinsmith et al, 2007). RANKL is a member of the tumour necrosis factor
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family and is an important regulator of osteoclast development. In terms of
mammary gland research, RANKL-null mice are unable to nurse their young
because of an inhibition of alveolar development during pregnancy. These mice
have decreased activation of the anti-apoptotic molecule AKT/PKB, they
exhibit an increase in alveolar cell death during pregnancy and a decrease in
cellular proliferation. Alveolar buds do still form in the RANKL-null mice
which suggests that RANKL is required for the later steps of alveolar
development i.e. differentiation (Hennighausen et al, 2005). Once RANKL is
upregulated by PR signalling, it signals downstream to induce expression of its
target NF-ĸB. NF-ĸB is required for the activation of the cell cycle regulator;
cyclin D1 via the kinase IĸB in neighbouring proliferative cells. The
RANKL/NF-ĸB/Cyclin D1 pathway is crucial for the formation of the alveolar
structures during pregnancy (Oakes et al, 2006). NF-ĸB is a transcription factor
which is widely used by eukaryotic cells as a regulator of genes that control cell
proliferation and cell survival thus it promotes the P/RANKL-driven
proliferation within the alveoli whilst also blocking apoptosis occurring
(Gonzales-Suarez et al, 2007). It is generally understood that NF-ĸB expression
and activity are tightly regulated during mammary gland development. This
strict regulation appears to be critical for mammary gland development and
tumourigenesis as genetically modified mice carrying alterations in proteins of
the NF-ĸB pathway show marked defects at different stages of pregnancy and
elevated NF-ĸB DNA-binding activity has been documented in both mammary
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cell lines and in primary human breast cancer tissues (Gonzales-Suarez et al,
2007).

1.6.(iv) Wnt4:
Wingless-related MMTV integration site 4 (Wnt4) is one of the 19 members of
the Wnt family of proteins. These Wnt proteins regulate a wide range of cellular
processes including proliferation and differentiation (Roarty et al, 2007). Wnts
participate in branching of other tissues, their transgenic overexpression affects
mammary branching and mammary targeted expression of an inhibitory form of
a Wnt receptor that blocks Wnt signalling suggests that at least one Wnt
signalling pathway is involved in mammary ductal development (Sternlicht et
al, 2006). Wnt4 is a well-known secreted glycoprotein that is regulated by
progesterone. It is a downstream mediator of the progesterone response and has
been shown to be coexpressed in PR positive cells (Hennighausen et al, 2005).
Mammary transplants of Wnt4-/- epithelium have demonstrated that Wnt4 acts
in a paracrine fashion to stimulate epithelial ductal side branching during early
pregnancy (Oakes et al, 2006). However, Wnt4 does not act alone in this as
these Wnt4 null mice are able to overcome the defects in late pregnancy hence
other PR-dependent signalling pathways also have a role to play in this response
(Hennighausen et al, 2005). Upon stimulation by the progesterone receptor,
Wnt4 can bind and upregulate the activity of its target; β-catenin. β -catenin has
specific actions in both the luminal and myoepithelial compartments of the
epithelium (Fig 1.10) (Oakes et al, 2006). Once upregulated via Wnt4, β-catenin
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will begin to accumulate in the cytoplasm. The accumulated β-catenin then
translocates into the nucleus, where it interacts with the DNA-binding T-cell
factor complex and can act as a transcriptional activator (Wong et al, 2002). In
addition to its role in transcription, Β-catenin is also a component of cell-cell
junctions and appears to have a role in signalling to luminal epithelial cells
(Oakes et al, 2006). Teuliere et al 2005 showed that activation of β-catenin
within the basal epithelial cells results in premature differentiation of the
luminal epithelium during pregnancy and persistent proliferation resulting in
tumours. These tumours consisted predominantly of undifferentiated basal cells,
which were amplified in response to β-catenin activation, thereby implicating
this molecule in cell fate decisions in the mammary gland (Oakes et al, 2006).

Fig 1.10: Molecular control of alveolar morphogenesis. Signalling from the progesterone receptor (PR)
and prolactin receptor (Prlr) is essential for alveolar morphogenesis in pregnancy. Increases in serum
progesterone (P) and prolactin (Prl) result in luminal cell proliferation during early pregnancy, which
continues throughout gestation. (a,b) Heterogenous receptor patterning is essential for complete alveolar
morphogenesis. (a) Wnt4 and RANKL are transcribed in response to Pgr signalling, probably in
cooperation with Prl signalling, and appear to stimulate proliferation of neighbouring cells via paracrine
mechanisms. (b) RANKL binds to its receptor RANK in a neighbouring cell and activates the
RANKL/nuclear factor (NF)-.B pathway, resulting in cyclin-D1 (Ccnd1) transcription and proliferation.
Wnt4 binds and activates its target ß-catenin, which has specific roles for both luminal and myoepithelium for cell fate decisions involving both proliferation and differentiation (Oakes et al, 2006).
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1.6.(v) Amphiregulin:
Amphiregulin is a gene that exhibited downregulation in the PRKO samples on
the Affymetrix microarray heat map that was carried out by the lab (Fig 1.8).
Amphiregulin is established as a promoter of mammary gland development but
it is upregulated during puberty when its expression is strongly induced by
estrogen (Sternlicht et al, 2006). Amphiregulin is an epidermal growth factor
receptor (Egfr) ligand and is exclusively expressed in the epithelium. EGFR is a
receptor tyrosine kinase that activates multiple intracellular pathways that are
often associated with cell proliferation and survival. EGFR activity is elicited
when it binds one of seven EGF-related ligands and then dimerizes with another
EGFR monomer or one of three related receptors ErbB2, ErbB3 and ErbB4.
Amphiregulin is the only EGFR agonist that is absolutely required for
mammary development as ductal outgrowth is impaired in Amphiregulin-null
mutant mice but not in mice lacking one or more alternative EGFR ligands. The
Amphiregulin deficient mice are unable to form a competent ductal tree that
fills the entire fat pad but instead form a small ductal outgrowth of insufficient
size to nourish pups (Sternlicht et al, 2006).
Amphiregulin is only expressed on mammary epithelial cells yet it has to bind
and activate EGFR on nearby but separate stromal cells. Amphiregulin is
expressed as a transmembrane precursor therefore for Amphiregulin to activate
adjacent stromal cells it has to be shed from the epithelial cell surface. ADAM
17 is a transmembrane metalloproteinase which proteolytically sheds
Amphiregulin from the epithelial cell surface to activate EGFR on the nearby
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stromal cells. EGFR phosphorylation can only occur when ADAM 17 and
Amphiregulin are expressed on mammary epithelial cells and EGFR is present
in the stroma (Fig 1.11). This signalling pathway is very important for
epithelial-stromal cross talk which acts to regulate mammary development
(Sternlicht et al, 2006).

Fig 1.11: A model diagram depicting Amphiregulin (AREG), Epidermal Growth Factor Receptor
(EGFR) and some of the other key endocrine and paracrine signals that regulate mammary
branching morphogenesis. Amphiregulin is expressed exclusively on the mammary epithelial cells
but it binds to EGFR on the adjacent stromal cells ADAM 17 is a metalloproteinase required to
activate AREG and enable it to interact with EGFR in the stroma and stimulate branching within the
gland (Sternlicht et al, 2006).

1.6.(vi) Elf5:
Elf5 is a member of the Elf subfamily of Ets transcription factors. Ets
transcription factors regulate gene expression during the differentiation of
multiple tissues including vascular, lymphoid, muscle and bone. Elf5 is
expressed specifically in the luminal cells of the mammary tissue and its
expression is increased dramatically during pregnancy to levels that far exceed
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those seen in other tissues (Oakes et al, 2006). Elf5-null foetuses die at
embryonic day 7.5 which points to a crucial function during embryogenesis.
Mice that have only one functional Elf5 allele show abrogated pregnancy
mediated alveolargenesis (Hennighausen et al, 2005). The levels of Elf5 are
reduced in prolactin receptor (PRLR) heterozygote mice but there is no similar
reduction in the expression of prolactin receptor in Elf heterozygote mice thus
indicating that Elf5 is downstream of the prolactin receptor (Oakes et al, 2006).
Retroviral re-expression of Elf5 in PRLR-/- MECs was able to completely
compensate for the loss of the PRLR signalling cascade. It is hypothesised by
Oakes et al, 2006, that Elf5 is a key mediator of structural and functional
development of lobuloalveoli and that it appears to be a master regulator of the
transcriptional cascade controlling alveolar morphogenesis (Oakes et al, 2006).
Since so much emphasis has been placed on Elf5’s importance in alveolar
morphogenesis, it was decided to analyse whether or not there was any
progesterone regulation involved in the induction of Elf5 in pregnancy thus
qPCR analysis was carried out on the Elf5 gene for this study.

The Anti-Proliferative Effectors of Progesterone Signalling:
Each of the branching agonists outlined have their own negative regulators
(Sternlicht et al, 2006). Negative regulators can be as important to normal
functional mammary gland development as their positive counterparts are.

36

1.6.(vii) TGF-β1:
Transforming growth factor beta (TGF-β) controls proliferation, cellular
differentiation and other functions in most cells. TGF-β is a secreted protein that
exists in three isoforms called TGF-β1 TGF-β2, TGF-β3. The cytokine TGF-β1
is an important regulator of mammary cell proliferation during pregnancy
(Oakes et al, 2006). TGF- β1 is a member of the transforming growth factor
beta superfamily which includes three TGFβs; activins, inhibins and bone
morphogenic proteins (BMPs) (Monks et al, 2007). TGF-β family members can
modify cell behaviours via autocrine, paracrine and endocrine mechanisms of
action (Ewan et al, 2005). TGF-β1 is restricted to the luminal epithelial cells
and can control cell proliferation via phosphorylation of Smad following TGF-β
receptor activation. The SMAD pathway is a classical signalling pathway that
TGF-β family members signal through to trigger apoptosis. TGF-β1 is a well
known negative regulator of mammary gland branching as it limits epithelial
proliferation and stimulates extracellular matrix production (Sternlicht et al,
2006).TGF-β1 heterozygote mice display accelerated lobuloalveolar
development due to increased proliferation indicating that the expression of
TGF-β1 restricts alveolar cell proliferation. Epithelial cell proliferation was
increased more than 15-fold in TGF-β1 null ovariectomized animals treated
with E&P compared to wild-type mice (Oakes et al, 2006). Previous studies
have revealed that activated TGF-β colocalizes with steroid-receptor containing
MECs thus suggesting that TGF-β may be one of several factors for preventing
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steroid-receptor containing MECs from entering the cell cycle and preventing
proliferation (Fernandez-Valdivia et al, 2005).
There is evidence from many species that both progesterone and TGF-β
suppress milk secretion during pregnancy however no formal link has yet been
made between the two. In this study, the expression of TGF-β is analysed in the
same manner as the previous positive regulators of proliferation to assess its
response, if any, to progesterone after three weeks of E&P treatment.

1.6.(viii) Sfrp2:
In addition to TGF-β, two other genes were observed in this study to further
explore the anti-proliferative effects that are in play in the mammary gland
during pregnancy. The first of these genes is known as Sfrp2 or secreted
frizzled-related protein 2. Secreted frizzled-related proteins (Sfrp) are a family
of secreted proteins that contain a region homologous to the extracellular
cysteine-rich domain of the Frizzled (FZD) family proteins (Wong et al, 2002).
As previously mentioned the Wnt genes encode a family of highly conserved
secreted proteins which modulate cell fate and behaviour in cells through
activation of receptor mediated signalling pathways (Wong et al, 2002).
Members of the Wnt family interact with seven-transmembrane receptors of the
Frizzled (FZD) family. Diverse signaling pathways are activated upon Wnt/FZD
binding. The Wnt ligand/FZD receptor interaction has been shown to induce the
phosphorylation of scaffolding proteins such as dishevelled, an event which was
reported to be a component of all Wnt-induced signaling pathways (Fig 1.12).
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The canonical Wnt signaling pathway leads to stabilization of its target βcatenin through inactivation of a protein complex consisting of, amongst others,
the tumor suppressors APC and Axin. This protein complex is destructive and
normally triggers rapid β-catenin phosphorylation, inducing its ubiquitination
and degradation. In the presence of canonical Wnt ligands, β-catenin is
stabilized, binds transcription factors of the LEF-1/T-cell factor (TCF) family,
and stimulates target gene transcription (Schlange et al, 2007).
The secreted frizzled-related proteins (Sfrps) are considered to be negative
regulators of the Wnt signaling pathway; they are extracellular inhibitors of Wnt
signaling, which compete with FZD receptors for ligand binding. Sfrps contain
a cysteine-rich domain (CRD) which is homologous to the putative Wnt-binding
domain, but lacks the transmembrane domain of frizzled proteins (Wong et al,
2002). Studies have suggested that deregulation of the Wnt pathway by a loss of
expression of the Sfrp proteins could lead to the development of breast cancer
(Schlange et al, 2007).
Fig 1.12: A simple schematic diagram
to illustrate the inhibition of Wnt
signalling pathway via Secreted
Frizzled-Related Protein (Sfrp), to
prevent transcription of the proliferative
signals i.e. Wnt, within the mammary
gland. Wnt signalling can activate a
common Wnt pathway component; the
scaffolding protein dishevelled (DVL)
(Schlange et al, 2007).
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1.6.(ix) Mig6:
The additional anti-proliferative gene observed in this study was mitogeninducible gene 6 (Mig6). Mig6 is also known as several other names; ERBB
receptor feedback inhibitor 1(Errfi1), receptor associated late transducer
(RALT) and gene 33 (Xu et al, 2006).Mig6 is present in higher-order species
but not in relatively less complex organisms suggesting that Mig6 has been
acquired during evolution for the needs of more-complex signaling circuits
(Zhang et al, 2007). Mig6 is an immediate early-response gene whose
expression can be rapidly and robustly induced by a variety of external stimuli
such as growth factors, cytokines and stress factors indicating that Mig6 may
play a critical role in the early regulation of many cellular responses (Zhang et
al, 2006; Ferby et al, 2006). Mig6 has been established as a tumour suppressor
gene and is found to be downregulated in various human cancers however the
reasoning behind the inclusion of Mig6 in this study arises from its role as a
negative regulator of epidermal growth factor signaling. Mig6 is a negative
regulator of the EGFR (Ferby et al, 2006). The EGFR is the receptor through
which the proliferative mediator; Amphiregulin, signals thus Mig6 may be a
possible negative regulator of proliferation during pregnancy-associated
mammary gland development, hence it became a gene of interest in this study.
Ferby et al 2006 showed that a deletion of the mouse gene encoding Mig6
caused hyperactivation of endogenous epidermal growth factor receptor (EGFR)
and sustained signaling through the mitogen-activated protein kinase (MAPK)
pathway, resulting in overproliferation and impaired differentiation of epidermal
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keratinocytes (Ferby et al, 2006). Mig6 can be transcriptionally induced by EGF
and it then acts as a negative feedback inhibitor of EGFR signaling by
downgrading EGFR tyrosine phosphorylation and the subsequent activation of
other downstream pathway targets. As well as the EGFR, Mig6 associates in
situ with its related receptors; members of the ErbB family and inhibits
signaling from these receptors as well; it also reduces the abilities of mitogens
in the Erb family to trigger cell proliferation and also to enter the cell cycle in
cultured cells and in vivo (Xu et al, 2006). Recently it has been reported that
downregulated expression of the Mig6 gene is observed in human breast
carcinomas, which correlates with reduced overall survival of breast cancer
patients. However since no mutations in the Mig6 gene have been detected in
human breast carcinoma, it was important to observe a normal Mig6 response in
relation to the ovarian steroids as well as the simulated pregnant state in the
hope of gaining a greater understanding of how and where it is exerting its
effects (Zhang et al, 2006).

As previously mentioned, much of the work in this study has revolved around
the original DNA microarray. The gene targets which have already been
discussed are mostly established targets of progesterone signalling yet their
expression in the mammary gland was being examined for the first time after 21
days of E&P treatment to determine their activity at this later and established
stage of pregnancy.
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1.7.The BDNF Study: A Novel Target of
Progesterone Signalling in the Mammary Gland
This section focuses on one particular novel target gene which has never before
been associated with the mammary gland or with pregnancy. This gene came to
the attention of the lab for exhibiting a strong P response in the microarray and
moreover because it was a well known neuronal gene. Brain derived
neurotrophic factor (BDNF) was significantly upregulated in the EP-treated
wild-type samples and its expression then decreased drastically in the EPtreated PRKO sample, in which PR had been totally ablated.

1.7(i) The Established Neuronal Functions of BDNF:
BDNF is a member of the neurotrophic family which are a group of small,
basic, secreted proteins that aid in survival and maintenance of specific neuronal
populations (Sohrabji et al, 2006). BDNF is widely distributed throughout the
brain and significantly impacts neuronal survival and function through a variety
of cell types to include neurons, astrocytes, oligodendrites, microglia and
endothelial cells. BDNF mRNA is localised to the cortex, hippocampus,
midbrain, hindbrain, cerebellum, olfactory bulb, spinal cord and the
hypothalamus. BDNF also promotes regeneration of adult sensory neurons,
retinal ganglion cells and basal forebrain cholinergic neurons following injury
(Sohrabji et al, 2006).
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The neurotrophins and their genes share homologies in sequence and structure.
The protein product of each gene includes a signal sequence and a prodomain
followed by a mature neurotrophin sequence. Each gene product must be
processed by proteolysis to form a mature protein (Reichardt, 2006). The BDNF
gene consists of 5 exons although the mature protein is entirely encoded by one
exon; exon number 5. All untranslated exons possess individual promoters,
resulting in a complex pattern of tissue and cell-specific expression of this
protein (Sohrabji et al, 2006).
The neurotrophins interact with two distinct classes of receptors. P75 was
identified as a low affinity receptor for all of the neurotrophins whilst the
members of the Trk subfamily of receptor tyrosine kinases were identified as
high affinity receptors for the neurotrophins. Trks are transmembrane receptors
with conserved intracellular domains that mediate several well-characterised
signalling pathways (Tapia-Arancibia et al, 2004). BDNF selectively binds to
TrkB by dimerizing the TrkB receptors which results in activation through
transphosphorylation of the kinases present in their cytoplasmic domains
(Reichardt, 2006). BDNF and TrkB mRNA expression varies as a function of
development, age and cognitive performance. In hippocampal cortical or
cerebellar granule neurons, BDNF can downregulate TrkB protein and/or TrkB
mRNA levels thus serving as some form of negative feedback mechanism
(Tapia-Arancibia et al, 2004).
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1.7.(ii) BDNF and the Ovarian Steroid Hormones:
Hormonal status can greatly influence the expression of BDNF. Estrogen
replacement in young adult, ovariectomized female rats increases BDNF
expression in the olfactory bulb, hippocampus, cortex, amygdale and the
septum. However other reports showed that high endogenous estrogen levels
during the estrus cycle are associated with decreased BDNF mRNA in the
hippocampus and prefrontal cortex. The estrogen-BDNF interactions remain
poorly understood and will require many more efforts to resolve. It is important
that attention is also given to the other ovarian hormones which may
significantly influence estrogen-BDNF interactions. It was noted that the timing
of high progesterone levels during the estrus cycle may be a critical switch for
increased or decreased BDNF expression (Sohrabji et al, 2006). Franklin and
Perrot-Sinal note that estrogen and progesterone act to impact BDNF levels in
the hippocampus as certain regions of the hippocampus express both
progesterone receptor mRNA and estrogen receptor mRNA (Franklin et al,
2006). Estrogen may also modulate BDNF protein levels through an estrogen
response element that has been identified in the BDNF gene in rats although it is
not clear if it is functional. The mechanism through which progesterone might
alter BDNF levels is still unclear. Progesterone might directly interact with PRs
present in the hippocampus or it may be on neurons in other areas that contain
PRs and project to the hippocampus (Franklin et al, 2006).
Unlike the other previous genes examined in this study, there is currently no
information or any publications on what role BDNF might play in the mammary
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gland. Even though, BDNF has been well established and documented as a
neuronal gene, in terms of mammary gland development it is still regarded as a
novel target gene. Interestingly, there has been some work done on BDNF in the
uterus where sympathetic neurite innervation is suppressed by high estrogen
levels. It appears that BDNF may mediate this neurite suppression. High levels
of estrogen induce BDNF expression in the uterus, which can be abolished by
blocking antibodies to BDNF thus suppressing sympathetic neurite outgrowth
(Sohrabji et al, 2006).

1.7.(iii) The BDNF Mammary Gland Hypothesis:
The strong expression profile produced by BDNF on the heat map came as an
unexpected surprise to the lab and immediately caused special interest. The
strong regulatory response of this secreted neuronal protein encouraged the lab
to hypothesise on what BDNF may be contributing to the progesterone
regulated mechanisms that seem to govern so much of the pregnancy-associated
mammary gland development and structure. In order to confirm and further
validate the microarray result, which demonstrated significant regulation by P in
many specific genes (Fig 1.8), the lab carried out qPCR analysis using similar
samples to those used in the microarray i.e. wild-type mice and PR mice of
varying genotypes that had been treated with E&P for three weeks (Fig 1.13a).
The lab also performed immunofluorescent staining techniques on wild-type
and PRKO mammary glands to determine whether there was co-localisation of
BDNF to PR within the gland. Their staining showed co-localisation of BDNF
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and PR in the ductal epithelium in the wild-type gland. As expected, the PRKO
mammary gland shows no functional PR activity and as a possible consequence
of this, no BDNF activity is seen either (Fig 1.13b).

(a)

(b)

Fig 1.13: (a) qPCR analysis showing BDNF expression in the mammary glands of wild-type (WT),
PRAKO, PRBKO and PRKO mouse models after three weeks of E&P treatment and (b)
immunofluorescent data produced by the Conneely lab which confirms BDNFs regulation by PR in the
mammary gland as BDNF is localised to PR in the luminal epithelium in the wild-type model but is
absent in the PRKO model when there is no functional PR present.

Once the regulation of BDNF by progesterone was further confirmed, the lab
generated BDNF conditional knockout transgenic mice in order to further
investigate where the effects of BDNF were being expressed downstream of the
progesterone receptor. The CRE-lox gene targeting approach was used in order
to specifically ablate expression of BDNF in the mammary glands of C55/129
mice. A heterozygous and homozygous conditional knockout for BDNF was
produced for the purposes of this study. In an attempt to understand the
response of BDNF to progesterone, the lab examined what happened to the
mammary gland in the absence of BDNF and then compared this to what
happened in the mammary gland in the absence of PR to try and functionally
connect the two.
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The role of BDNF as hypothesised by our lab therefore arises from the two
opposing phenotypes that were seen in the PR-/- mice and BDNF-/- mice
generated by the lab (Fig 1.14).

Fig 1.14: Schematic diagram depicting the phenotypical characteristics of mammary gland development
i.e. branching and alveolar differentiation in three mice models with varying genotypes (a) PR
homozygous knockout, (b) normal murine model, (c) BDNF homozygous knockout.

When PR is removed, no side-branching or alveolar differentiation can occur
during pregnancy in the absence of a progesterone signal. It is hypothesised that
the proliferative signals; Amphiregulin, RANKL and Wnt4, may be
downregulated in the absence of functional PR therefore they may be involved
in the loss of proliferation within the mammary gland.
When functional BDNF is conditionally removed from the mammary gland, a
very different phenotype is produced. Despite its own regulation by
progesterone, the BDNF knockouts do not affect branching in the same manner
as progesterone knockouts. In the absence of BDNF, there is a hyperbranching
phenotype with increased ductal side branching and alveolar differentiation (Fig
1.15a). The BDNF knockout models also demonstrate reduced cellular polarity,
which is often associated with the initial stages of tumour formation (Fig 1.15b).
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The hypothesis suggests that progesterone simultaneously upregulates BDNF
expression along with its upregulation of the proliferative signals except that the
presence of BDNF is there to limit and control the proliferation induced by
Amphiregulin, RANKL and Wnt4.

Fig 1.15: (A) Comparison of mammary gland morphogenic responses in wild-type (WT) and
BDNF-/- ovariectomized mice treated for 21 days with pregnancy levels of E & P. In the absence of
BDNF, the mammary gland exhibits hyperbranching of secondary epithelial ducts compared to the
normal ducts in the WT (purple arrows). (B) This staining shows the cellular structure of the WT
and the BDNF knockout samples, the lumen seems to be filled with cells suggesting the normal
cellular mechanisms for moving dead cells out of the lumen may be inhibited (red cells) and there
also seems to be a loss of cell-matrix interactions in the stroma (blue arrows)

It is important that these powerful signals can be maintained and curtailed in
order to preserve the proper structure and spacing of the ductal branches as they
develop within the gland. BDNF is believed to monitor and curb the
proliferation within the developing gland. Without BDNF, the ductal branches
may grow and expand uncontrollably which can create potential for aberrant
growth patterns and tumour formation. The hypothesis of BDNF regulation by
PR is illustrated in Fig 1.16.

48

Fig 1.16: Schematic diagram of the hypothesis of BDNF regulation by the progesterone receptor (PR)
and its functional role in relation to mammary gland development

1.7.(vi) BDNF and the Progesterone Response Element (PRE):
The sequence of the BDNF gene was analysed to determine whether or not it
had a progesterone response element in its promoter region as previous work in
the BDNF field has identified the presence of an estrogen response element. The
5’ sequence flanking exon1 of the BDNF gene was analysed for potential PRE
sites and showed very high sequence homology between the human and the
mouse (Fig 1.17). The progesterone response element sequence is a palindromic
sequence separated by three variable nucleotides; 5’TGTTCTnnnTCTTGT 3’.
A half-site PRE was found within the BDNF promoter region and was
conserved between both species. Since the estrogen receptor is capable of
binding to half sites, it is possible that progesterone receptor could be able to do
the same. The presence of a conserved PRE on the BDNF promoter region
strongly infers that BDNF transcription can be driven directly by PR.
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Fig 1.17: Identification of the PRE half site on the 5’ sequence flanking exon1 of the BDNF gene of
both the mouse and human. The half site was found at position 893 on the mouse gene and on position
1172 on the human gene – the presence of the PRE half site confirms the regulation of BDNF by PR in
the mammary gland

1.8. Progesterone Receptor Signalling Targets in
the Uterus
Progesterone and its role in mammary gland development has been the main
focus of this study up to now however the uterus is also a known target of
progesterone action therefore it was chosen to use as a comparison to determine
if progesterone operates in a similar or dissimilar way in other important
reproductive tissues when compared to the mammary gland. These comparative
observations of progesterone tissue specific function should aid in a greater
understanding of this very powerful ovarian steroid hormone.

1.8.(i) The Uterus:
The endometrium functions as a lining for the uterus; it is susceptible to many
hormonal changes and is the focal point of this uterine study. The histology of
the endometrium consists of a single layer of columnar epithelium, resting on a
layer of connective tissue, which varies in thickness according to hormonal
influences – this is known as the stroma (Lee et al, 2006). Simple tubular
uterine glands reach from the endometrial surface through to the base of the
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stroma, which also carries a rich blood supply of spiral arteries. In a woman of
reproductive age, two layers of endometrium can be distinguished. The
functional layer is adjacent to the uterine cavity. This layer is built up after the
end of menstruation during the first part of the previous menstrual cycle.
Proliferation is induced by estrogen (follicular phase of menstrual cycle), and
later changes in this layer are engendered by progesterone from the corpus
luteum (luteal phase). It is adapted to provide an optimum environment for the
implantation and growth of the embryo. This layer is completely shed during
menstruation. The basal layer, adjacent to the myometrium and below the
functional layer, is not shed at any time during the menstrual cycle, and from it
the functional layer develops. In the absence of progesterone, the arteries
supplying blood to the functional layer constrict, so that cells in that layer
become ischaemic and die, leading to menstruation (Lee et al, 2006).
Embryo implantation is a critical uterine event in which the blastocyst attaches
to the luminal epithelium of the endometrium and then invades into the stroma
(Franco et al, 2008). During the menstrual cycle or the estrous cycle, the
endometrium grows to a thick, blood vessel-rich, glandular tissue layer. During
pregnancy, the glands and blood vessels in the endometrium further increase in
size and number. Vascular spaces fuse and become interconnected, forming the
placenta, which supplies oxygen and nutrition to the potential embryo and fetus.
The stromal cells surrounding the blastocyst undergo a proliferation and
differentiation program to become decidual cells (Franco et al, 2008). The
decidua is the mucous membrane which lines the uterus and undergoes
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modification during pregnancy (Franco et al, 2008). Embryo implantation will
only occur when the developmental progression of the hatched embryo to the
activated blastocyst stage is precisely synchronised with the differentiation of
the uterus to the receptive state. This restricted time period is termed the
window of receptivity and its onset is controlled by the sequential and
synergistic actions of ovarian estrogen and progesterone (Fernandez-Valdivia et
al, 2005). In the mouse, the periimplantation period can be divided into
prereceptive, receptive and refractory with implantation occurring at day 4 of
pregnancy. Uterine development of the prereceptive period is under the
influence of progesterone stimulation; progesterone levels increase at this point
as progesterone is released form the newly formed corpus luteum (Takamoto et
al, 2002; Franco et al, 2008). During this progesterone-dominated period, a
nidatory period surge of estrogen is required to confer endometrial receptivity to
the sensitized uterus, facilitating the implantation (Takamoto et al, 2002).
Embryo attachment is followed by a characteristic endometrial transformation,
decidualisation, which involves both differentiation and cell proliferation. PR
action is indispensable whereas ERα is not essential. In the mouse, progesterone
appears to prime the endometrium for before embryo attachment/implantation
and thus is one of the essential functions regulated by progesterone during the
periimplantation period (Takamoto et al, 2002). In the uterus, progesterone is
also involved in the suppression of uterine proliferation which is induced by the
effects of estrogen (Franco et al, 2008). Just as in the mammary gland, PR
operates in a paracrine fashion in the uterus. Progesterone projects its influence
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indirectly via paracrine molecular pathway: stromal to epithelium in the uterus
and intraepithelial in the mammary gland (Fernandez-Valdivia et al, 2005).

1.8.(ii) PR Knockout Mouse Models and the Uterus:
As with the mammary gland, PR knockout mouse models were used to study
the role of PR in the uterus. Female PRKO mice are infertile with defects in
multiple reproductive tissues. These mice had an abnormal response to E&P
treatment, they failed to ovulate and their uteri failed to support implantation as
was demonstrated by an inability to undergo an artificially induced decidual
response (Lee et al, 2006; Franco et al, 2008). Studies which used selective
ablation of specific PR isoform indicated that PR-A is the functional isoform in
the uterus and the major mediator of progesterone signalling (FernandezValdivia et al, 2005). PRAKO mice developed normally to adulthood but were
infertile, their uteri also failed to undergo the artificially induced decidualisation
reaction and some progesterone target genes associated with uterine receptivity
were downregulated (Franco et al, 2008). PR-B expression was not increased in
these mice indicating that there was no compensation however selective
activation of PR-B in the PRAKO mice resulted in an abnormal P-dependent
induction of epithelial proliferation. This gain of proliferative activity by
removal of PR-A indicated that PR-A is required not only to inhibit E-induced
hyperplasia of the uterus but also to limit potentially adverse proliferative
effects of the PR-B isoform (Fernandez-Valdivia et al, 2005). Observations
from the PRBKO mice indicate that they also developed normally, they were
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fertile and carried successful pregnancies and they did demonstrate the
antiproliferative effects of progesterone upon treatment with E&P (Franco et al,
2008). The specific PR isoform knockouts seem to indicate that the two
isoforms have discrete and non-overlapping functions as PR-A is the
predominant form of PR in the uterus whilst PR-B remains the predominant
isoform in the mammary gland (Lee et al, 2006).

Effectors of PR Action in the Uterus:
Although progesterone seems to regulate the uterus and the mammary gland in
distinctly different ways, the goal of this comparative section aims to seek out
some common threads between the two whilst also elaborating on the differing
signalling mediators in the uterus. Amphiregulin, RANKL and Wnt4 were all
targeted in the uterus to determine what expression pattern may be produced.

1.8.(iii) Amphiregulin:
As in the mammary gland, Amphiregulin binds to the EGFR and was found to
be transiently expressed in the luminal epithelial cells of the murine uterus at the
time of implantation. Areg-/- mice were viable and fertile suggesting that there
must be redundancy among the EGF family of ligands working within the
uterus (Franco et al, 2008).

54

1.8.(iv) Wnt4 and BMP2:
Wnt4 expression increases with decidualisation in both mouse and human.
Wnt4 expression seems to be localised to the stromal cells of the uterus and
knockdown of Wnt4 in the human endometrial stromal cells prevented in vitro
decidualisation (Franco et al, 2008).
In the uterus, Wnt4 has been identified as a downstream target of BMP2. Bone
morphogenetic protein 2 is a member of the BMP family of morphogens and
has been shown to be expressed in the uterine stroma at the site of attachment
(Franco et al, 2008). Conditional ablation of BMP2 in the uterus produced
infertile female mice. Embryos were able to attach to the uterine luminal
epithelium but were unable to implant due to a failure of decidualisation
(Franco et al, 2008).

1.8.(v) Indian Hedgehog:
Indian hedgehog (Ihh) has been identified as an important effector of PR action
in the uterus. Ihh is a member of the Hedgehog (Hh) family of morphogens. In
general, Hh signalling regulates both cell proliferation and differentiation by
either short range or long range actions as Hh protein is diffusible. Ihh has been
identified as a downstream target of PR in the uterus (Takamoto et al, 2002).
Ihh is acutely induced in the luminal epithelium and glandular epithelium by P
with an expression profile that peaked right before the time of implantation and
decreased immediately after implantation (Takamoto et al, 2002; Franco et al,
2008). The expression of Ihh preceded the expression of other P target genes.
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Known Hh target genes Patched-1 (Ptc-1), Hedgehog Interacting Protein 1
(HIP1) and Chicken Ovalbumin Upstream Promoter-Transcription Factor II
(COUP-TFII) were shown to be regulated in a temporal manner similar to Ihh.
Ptc-1 and HIP1 were found in the luminal epithelium and the stroma whereas
COUP-TFII was found only in the stroma thus suggesting that Ihh may be a
major effector of PR signalling in the uterus (Franco et al, 2008). Also with Ihh
expressed in the epithelium and its targets expressed in the stroma suggests that
Ihh may act as a mediator of epithelial-stromal cross-talk in the uterus (Franco
et al, 2008).
Previous studies which used the Cre/lox system of gene targeting highlighted
the importance of Indian hedgehog to PR signalling in the uterus. A floxed
allele of Ihh was generated and the resulting mouse was crossed to a PR-Cre
mouse. The resultant phenotype of these mice was almost identical to that of the
PRKO uterus. The uteri of Ihhd/d mice were unable to support embryo
implantation and they were unable to undergo the artificially induced
decidualisation reaction (Franco et al, 2008).

1.8.(vi) Hoxa10:
Another effector of P-regulated action in the uterus is the transcription factor
Homeobox A10 (Hoxa10) (Lim et al, 1999). Hoxa10 is a member of the AbdBlike Hoxa gene family that have an important role in development. Hoxa10 is
expressed in the luminal and glandular epithelium on day 0.5 to day 2.5 of
pregnancy. It is also strongly expressed in stroma and decidua of the pregnant
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mouse uterus (Lim et al, 1999). Hoxa10 expression then persists through day
4.5 to day 7.5 in the developing decidua. Hoxa10 knockout female mouse
models were subfertile (Franco et al, 2008). At the time of implantation, most
embryos were small and degenerating with almost half of them unattached. The
embryos that had attached resulted in abnormal implantation sites on days 6.4 to
8.5 suggesting that Hoxa10 is required for successful embryo implantation
(Franco et al, 2008). Also decidualisation of the uteri in the Hoxa10 knockouts
was severely compromised during embryo implantation demonstrating an
additional role for Hoxa10 in early pregnancy (Franco et al, 2008). Previous
studies have shown that Hoxa10 is induced in the mouse uterine stroma within 4
hours of a P injection in a protein-synthesis dependent fashion and that the
upregulation of Hoxa10 by P is inhibited by the PR antagonist RU-486
suggesting a requirement for PR for this induction. These studies imply that
Hoxa10 is a primary responsive gene and is involved in implantation as a direct
mediator of P action (Lim et al, 1999).
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1.9. General Aims of the Study:
•

To uncover downstream mediators of the progesterone response in the
pregnant mammary gland using the results obtained from an Affymetrix
microarray previously carried out by the lab on PRKO mice versus wildtype mice.

•

To hypothesise a functional role for the novel target; BDNF, in
pregnancy-associated mammary gland development.

•

To examine the progesterone regulated response of genes in another
reproductive tissue; the uterus and compare these results to those
observed in mammary gland.

1.9.(i) Specific Aims of the Study:
•

Analyse known progesterone-regulated target genes from the Affymetrix
microarray to observe their differential expression between wild-type
and PRKO mammary glands using quantitative PCR techniques. The
target genes are divided into proliferative genes; RANKL, Wnt4,
Amphiregulin and Elf5, and also into anti-proliferative genes; TGF-β1,
TGF-β2, Mig6 and Sfrp2.
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•

Analyse these known progesterone-regulated target genes after 21 days
of estrogen and progesterone treatment to assess their differential
expression profiles in the mammary gland during a simulated pregnant
state

•

Use quantitative PCR techniques to elucidate the hypothesised role of
the novel progesterone target gene; BDNF as proposed by the lab.

•

Analyse the expression of well-known progesterone-regulated target
genes in conditional BDNF knockout mouse models to further elucidate
how BDNF may be functioning in the mammary gland. The proliferative
target genes; RANKL, Wnt4 and Amphiregulin were analysed.

•

Compare the proliferative and differentiating role of progesterone in the
uterus and the mammary gland using the differential expression profiles
of commonly expressed target genes; RANKL, Wnt4, Amphiregulin,
Mig6

•

Use quantitative PCR techniques to further investigate the expression
profiles of the non-comparative, rapidly induced genes by progesterone
in the uterus; Indian hedgehog, BMP2, Hoxa10.
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2. Materials and Methods
2.1. Mouse Models and Hormone Treatments:
The strain of mice used in this research is known as C55/129. The PRKO mouse
model has been used for a long time to investigate the role of progesterone in
the mammary gland; it is regarded as an indispensable tool for any signalling
pathway investigations. The PRKO mouse model is generated by ablation of
both isoforms of PR using gene targeting techniques (Ismail et al, 2003). The
resultant mice are usually bred from a heterozygous female and a homozygous
or heterozygous male to produce both PRKO and PRKO+/- genotypes, both of
which were used in the uterus study. Constitutional ablation of PR function did
not affect embryonic and postnatal development of female and male PRKOs
because both sexes progressed to adulthood at normal Mendelian frequencies
(Fernandez-Valdivia et al, 2005). Due to the viability of the PRKO models,
there was no need to use the sophisticated Cre/lox targeting approach.
However, the Cre/lox system was also used to generate the isoform specific
knockout mouse models; PRAKO and PRBKO which were used in the uterus
study and were generated in house. The Cre/loxP-gene targeting approach was
used in embryonic cells to introduce a point mutation into the PR gene at the
ATG codon encoding Met1 in order to specifically ablate expression of the PRB protein and then at the ATG encoding Met166 in order to specifically ablate
expression of PR-A.
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The BDNF mice were also generated by crossing a MMTV-Cre mouse with a
floxed BDNF mouse; a floxed BDNF mouse is one in which the BDNF gene is
flanked by lox sites which will be ablated when crossed with the Cre mouse.
The BDNF knockout mice were conditional knockouts hence the cohort of mice
had a specific ablation of the BDNF gene in the mammary gland. These mice
were also selectively bred to produce both homozygous and heterozygous
knockouts.
All animals were generated, reared and housed at the Baylor College of
Medicine Animal Facility. All of the mice were weaned at three weeks of age
and genotyped. At six weeks of age, the mice underwent surgical ovariectomies
followed by ten days of rest. The surgery curtailed any endogenous production
of ovarian steroid hormones which could adversely affect the results of the
various studies.
The ‘E&P treated’ mice which, were used for the mammary gland studies,
received daily subcutaneous injections of 1mg of progesterone and 250ng of
estrogen in 50µL of corn oil. The ‘P treated’ mice which, were used for the
uterus study, received one subcutaneous injection of 1mg of progesterone in
50µL of corn oil. The ‘control treated’ mice were treated with 50µL of corn oil
alone. All of the mice were sacrificed with CO2 once their term of treatment
concluded and the tissues of interest were surgically removed by a technician.
The tissue samples were then labelled and stored in eppendorf tubes at -80ºC for
RNA extraction.

61

2.2. Protocol for RNA Extraction from Frozen
Tissue
2.2.(i) Materials:
•

PowerGen* Model 125 Homogeniser (Fisher Scientific, USA)

•

Beckman J2-HS Floor Model Centrifuge C0706037 (Beckman Coulter,
USA)

•

Trizol® Reagent, Cat# 15596-018 Lot#50300417 (Invitrogen, USA)

•

Chloroform (C298-1) Lot# 982778 (Fisher Scientific, USA)

•

2-Propanol (A416-1) Lot# 992220 (Fisher Scientific, USA)

•

Portable Pipet Aid Serial# 0152299 (Drummond Scientific Co. USA)

•

Pipetman® p200 M10627C (Gilson Inc, France)

•

Pipetman® p1000 E11507C (Gilson Inc, France)

•

DEPC Water (Made in-house, see Appendix)

•

75% DEPC Ethanol (Made in-house, see Appendix)

2.2.(ii) Preparation for the day of extraction:
The allocated bench space was cleared of anything unrelated to the protocol.
The bench and all labware and materials were sprayed with RNase Zap and left
for 15 minutes. All the tubes and tips used in the RNA work were RNase-free
and all were autoclaved. Required aliquots of the necessary reagents were made
up before beginning the extraction procedure. The homogenisation step required
a number of 20ml DEPC water washes, the DEPC water was measured in 50 ml
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Falcon tubes. There was one wash for each tissue sample, one extra wash for
each change of genotype as well as six start washes and six end washes.
Other reagents required were aliquoted out as follows:
•

Trizol® (2ml per gland with a max of 4mls)

•

Chloroform (0.2mls per 1ml of Trizol®)

•

2-Propanol (0.5mls per 1ml of Trizol®)

•

75% DEPC ETOH (1ml per 1ml of Trizol®)

2.2.(iii) Preparation of frozen tissue for extraction:
Two plastic SARSTEDT tubes were labelled for each sample – the sample
number was written on the lid and three times on the base as Trizol® can
dissolve ink. The homogeniser was washed three times with DEPC water and
then once with Trizol. The homogeniser was operated at 75% of its potential
speed and each wash lasted for an average of 15 seconds. The frozen tissue
samples were taken from the freezer and placed on ice. The autoclaved pipette
tips were used as forceps to separate the frozen tissue and remove it from the
eppendorf tube. This step must be done quickly to prevent the other additional
tissue samples from thawing out. The tissue was immersed in a tube with 2mls
of Trizol® and placed on ice. The tissue samples were homogenised until there
were no clumps and the solution had a ‘soupy’ appearance. The tubes were then
returned to ice. The homogeniser was washed with one 20ml DEPC wash
between each sample and two washes were used between each genotype. When
all samples had been homogenised, the homogeniser was washed three times
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with DEPC water and once with 70% ethanol to clean off any fat or residue
from the probe.

2.2.(iv) Extraction of the RNA from the homogenised tissue
samples:
The tissue was removed from ice and placed in a rack at room temperature for
10 minutes. 0.2ml Chloroform per 1ml of Trizol® was pipetted into each tube
and the tube was shaken vigorously by hand for about 30 seconds. The samples
were left for 5 minutes at room temperature. The samples were then centrifuged
at 2-8°C at 12,000 x g for 15 minutes. The aqueous phase was retained and
transferred to a fresh labelled tube using a 1ml pipette. 0.5ml of 2-Propanol per
1ml of Trizol® was pipetted into the tube and swirled gently. The sample was
centrifuged at 2-8°C at 12,000 x g for 10 minutes. The tube was checked for an
RNA pellet and the supernatant was carefully poured off. The pellet was washed
with 2mls of 75% ETOH (DEPC) – at least 1 ml of ethanol was added for every
1ml of Trizol®. The samples were centrifuged at 10,000 rpm for 5 minutes. This
ethanol wash was repeated once more. The supernatant was then discarded – the
lip of the tube was wiped with a kemiwipe. The tubes were inverted on a
kemiwipe and the RNA pellets were allowed to air dry for about 5 – 10 minutes.
The pellet was resuspended in 100µL of RNase free water. The samples were
incubated on ice for 1 hour. The extracted RNA samples were stored at -80°C.
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2.3. Protocol to Determine the Concentration of
the RNA Samples
2.3.(i) Materials:
•

Beckman Coulter DU800 Spectrophotometer (Beckman Coulter, USA)

•

Pipetman® p200 M10627C (Gilson Inc, France)

•

Reusable DU800 cuvettes (Beckman Coulter,USA)

•

Double Distilled Water (Made in-house)

2.3.(ii) Analysis of the RNA using the DU800
Spectrophotometer:
The UV light of the spectrophotometer should be turned on for about 10
minutes before use. The cuvette was washed out with double distilled water and
filled with 100µL of the sample blank – the sample blank must be the same as
the diluent that was used to resuspend the extracted RNA i.e. Rnase free water.
The cuvette was placed in the spectrophotometer in correct orientation to the
UV light. The sample blank is named as ’blank’, the ’blank’ was then blanked
and read. The cuvette was washed out with the double distilled water for reuse
with the next sample. 5 µL of the RNA sample was diluted into 95µL of Rnase
free water, this was pipetted into the cuvette, named and read. The cuvette was
washed out again and subsequent samples are named and read. The results were
then exported to a Microsoft Excel spreadsheet and saved (Fig 2.2).
UV spectroscopy is the traditional method for assessing RNA concentration and
purity (http://www.ambion.com/techlib/tn/94/949.html). The absorbance of a
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diluted RNA sample is measured at 260 and 280 nm. The nucleic acid
concentration is calculated using the Beer-Lambert law, which predicts a linear
change in absorbance with concentration.
Figure 2.1: Beer-Lambert
Law for calculating UV
absorbance by nucleic acid
(http://www.ambion.com/techl
ib/tn/94/949.html).

Using this equation, an A260 reading of 1.0 is equivalent to ~40 µg/ml singlestranded RNA. The A260/A280 ratio is used to assess RNA purity and is
dependent on both pH and ionic strength. As pH increases, the A280 decreases
while the A260 is unaffected. This results in an increasing A260/A280 ratio. Water
often has an acidic pH, which lowers the A260/A280 ratio. An A260/A280 ratio
between 1.8 and 2.1 is indicative of highly purified RNA when the RNA is
diluted with Rnase free water at a pH of 6 – 7
(http://www.ambion.com/techlib/tn/94/949.html).

2.3.(iii) Formulas to determine the RNA concentrations:
•

Concentration of RNA in µg/ml:

•

40 µg/ml x A260 x dilution factor

•

Concentration of RNA in µg/µL:

•

(40 µg/ml x A260 x dilution factor)/1000
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•

Total amount of RNA present in the sample:

RNA conc. x sample vol (mls or µls depending on the conc. units)

Fig 2.2: Example of a read-out from the UV spectrophotometer which calculates the
absorbance of the RNA samples at 260nm. The samples are identified by their original mouse
numbers. Absorbance is measured at 280nm and 260nm as nucleic acids absorb UV light at
these wavelengths. The 260:280 ratio measures RNA purity, a value between 1.8 and 2.1
indicates high quality RNA. The data is then exported into an Excel sheet to determine RNA
sample concentration using Beer Lamberts Law.

2.4. Protocol to Determine the Quality of the RNA
Samples
2.4.(i) Materials:
•

EC 400 Power Source (E-C Apparatus Corporation, USA)
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•

Ultrapure™ Agarose 500gm Cat# 15510-027 Lot# D030507
(Invitrogen, USA)

•

Stovall Hybridization Water Bath (Life Science Inc, USA)

•

Sanyo Microwave

•

Orange sample denaturing buffer containing ethidium bromide (Made
in-house, see Appendix)

•

10X TBE buffer solution

•

Double Distilled Water

•

Bromophenol Blue Loading Solution (Promega Corporation, USA)

•

Loading buffer (made in-house)

•

Pipetman® p20 Z53746B (Gilson Inc, France)

•

Pipetman® p200 M10627C (Gilson Inc, France)

2.4.(ii) Preparation of a 0.8% agarose gel:
The water bath was turned on and set to 65ºC. 0.48g of agarose powder was
weighed out onto an electronic scale and was tipped into a conical flask. 6mls of
10X TBE running buffer was added to the conical flask. The gel solution was
then made up to 60mls with 54mls of double distilled water. The gel solution
was then boiled in the microwave for 2 minutes. The gel solution was then left
to cool to 65ºC. The agarose gel was then poured into the plastic mould. It is
important to ensure there are no air bubbles present. The gel is left to set for 30
minutes.
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2.4.(iii) Sample preparation for loading onto the agarose gel:
3µl of each RNA sample was pipetted into 20µl of orange sample denaturing
buffer in a 0.5ml eppendorf tube. Samples were then heated at 65ºC in the water
bath for 15 minutes and then placed on ice. 2µl of a bromophenol blue loading
solution was added to each sample to track the migration of the mRNA during
electrophoresis. Samples were spun for a few seconds before loading onto the
gel.

2.4.(iv) Loading of samples onto the agarose gel:
One litre of 1X TBE buffer was made up using double distilled water. The set
agarose gel was placed horizontally onto the platform of the gel container. The
container was filled with 1X TBE (~400mls) ensuring that the surface of the gel
is flooded. The full sample amount (25µl) was loaded into each well of the gel.
Electrodes were attached to the container at either end – the black electrode is
always attached at the back. The gel was run with 1X TBE at 110V for 30
minutes (the gel should not be run any longer as it may cause the RNA to
degrade). After 30 minutes, the gel was photographed using an Alphamager
camera and software – the presence of two clear bands of ribosomal RNA; 28S
and 18S indicate good quality RNA.
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Alternative Agarose Protocol with Ambion Glyoxal Load Dye:
Make a 1% agarose gel with 1µL of 0.5µg/ml ethidium bromide. Mix the RNA
sample 1:1 with the loading dye and heat at 55ºC for 30 minutes. Load onto the
gel and run for 30 minutes.

2.5. Protocol for Reverse Transcription PCR of
Extracted RNA to Generate cDNA
2.5.(i) Materials:
•

DNA Thermal Cycler 480 (Perkin Elmer)

•

High Capacity cDNA Reverse Transcription Kit Lot# 0710032
(Applied Biosystems, USA)

•

Ribonuclease Inhibitor (cloned) Cat# 15518-012 Lot# 283324
(Invitrogen,USA)

•

Pipetman® p20 Z53746B (Gilson Inc, France)

•

Pipetman® p200 M10627C (Gilson Inc, France)

•

Pipetman® p1000 E11507C (Gilson Inc, France)

•

Nuclease-Free Water (Ambion, USA)

2.5.(ii) The Reverse Transcriptase PCR (RT-PCR):
Before beginning, it was very important to determine a balance between the
final volume of cDNA that was needed for the number of qPCRs that were
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expected to be run and how many µg’s of the extracted RNA that can be used in
preparing the cDNA. The minimum amount of RNA that can be used in a RTPCR reaction is 0.002µg/µl whilst the maximum amount of RNA that can be
used in a RT-PCR reaction is 2µg/µl. The actual amount of RNA that is used
generally depends on how abundant the resultant target sequence is expected to
be.
The concentration of the RNA included in the RT-PCR reaction was 6µg
RNA/60µl sample solution. The sample solution therefore contained 6µg of
RNA, Rnase free water and Rnase inhibitor which was made up to a final
volume of 60µl (Fig 2.3).
A: RT RNA Sample Solutions

B: NRT RNA Sample Solutions

Fig 2.3: An example of a Microsoft Excel spreadsheet showing the volumes of RNA that are required to
make up the RNA sample solutions required to generate cDNA. Fig 2.3A shows the “reverse
transcriptase” (RT) sample solutions and fig 2.3B shows the “no reverse transcriptase” (NRT) solutions.
The RT sample solutions have a RNA concentration of 6µg/60µl whilst the NRT sample solutions have a
RNA concentration of 4µg/40µl. The remaining solution volume is made up with the Rnase free water
and Rnase inhibitor. Equal amounts of the RT/NRT RNA sample solution will be added to the
appropriate RT/NRT mastermix to generate the required volume of cDNA. The RNA standards (STD)
are required to generate a standard curve for the qPCR. The stock concentration of these standards is
1µg/µl. 12µl of the RNA standards are added to the sample solution, this creates a concentration of
12µg/120µl, when added to the mastermix thus their final concentration for the qPCR is 100ng/µl.
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The RNA samples were prepared separately to the RT-PCR mastermix. A
second set of the RNA sample solutions were also prepared to be used as
negative controls for the experiment, these samples were also added to an equal
volume of mastermix but their mastermix lacked any of the reverse transcriptase
enzyme hence these RNA samples could not undergo the RT-PCR reaction thus
no DNA was expected to be generated in these samples. These samples were
known as “no reverse transcriptase” (NRT). The final volume of the sample
solution for the NRT samples was 40µl as opposed to 60µl; this was done in
order to conserve reagents.

Other RNA samples which were also prepared for RT-PCR included an RNA
standard which was prepared in triplicate and also an RTnoRNA sample which
served as another negative control to ensure that no of the RT reagents were
contaminated. The standard RNA samples were selected to undergo RT-PCR
and generate cDNA so that they could be used in the qPCR to generate a
standard curve in order to quantify the other cDNA samples. Mouse Universal
RNA is commercially bought and used as a standard for the qPCR experiments.
Universal RNA refers to total RNA controls which are derived from whole
tissue sources. Since mice are the animal model of choice in this study, the
species of the universal RNA is also mouse and it is made by pooling the total
RNA extracts from a collection of different murine tissues, thus providing the
broadest coverage of expressed genes in the mouse. The stock concentration of
the universal RNA is 1µg/µl, a serial dilution of this was sufficient for the RT-
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PCR. The concentration for the RT-PCR step was therefore 12µg of Universal
Mouse RNA for the RT standards samples and 8µg for the NRT standard
samples. The final concentrations of RNA standards that underwent the RTPCR reaction were therefore 12µgRNA /120µl and 8µg RNA/80µl which
equates to 100ngRNA /µl of cDNA standard.

The RT-PCR mastermix kits had to be thawed out on ice for at least one hour.
Two separate RT-PCR mastermixes were prepared for the RT samples and the
NRT samples as follows: An equal volume of mastermix had to be added to
each sample solution hence the RT mastermix had a final volume of 60µl whilst
the NRT mastermix had a final volume of 40µl. In the NRT mastermix, RT is
substituted with Rnase free water.
Each mastermix (RT and NRT) were prepared in a 2ml eppendorf tube – extra
volume was added to allow for pipetting error.
Vol of reagents for 1 RT reaction
10X RT buffer
12µl
25X dNTPs
4.8 µl
10X oligo dTs
12µl
Rnase free water
25.2 µl
Reverse Transriptase
6 µl

Vol of reagents for 1 NRT reaction
10X RT buffer
8 µl
25X dNTPs
3.2 µl
10X oligo dTs
8 µl
Rnase free water
16.8 µl
Rnase free water
4 µl

The RT-PCR master mix is bought commercially and comes as 2X but addition
of the RNA sample solution dilutes it to 1X. The final volume for the reaction
was established at 120µl (60µl of sample + 60µl of mastermix) for the RT
samples and 80µl (40µl of sample + 40µl of mastermix). The sample solutions
and the appropriate mastermix were mixed together in 0.5ml eppendorf tubes,
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the samples were then briefly centrifuged to spin down the contents and
eliminate any air bubbles. The reaction tubes were placed in the PCR machine
for a 2hr cycle:
•
•
•
•

25ºC for 10mins
37ºC for 120mins
85ºC for 5secs
4ºC for ∞

Once the RT-PCR reaction was complete, the samples were stored overnight at
4ºC. The remaining RNA samples were stored in the -80ºC freezer.

2.6. Protocol for the Analysis of the cDNA
Samples via quantitative PCR Methodology.
2.6.(i) Materials:
•

MicroAmp™ Fast Optical 96 Well Plate with Barcode 0.1ml Part#
4346906 (Applied Biosystems, USA)

•

Optical Adhesive Covers Part# 4360954 (Applied Biosystems, USA)

•

StepOnePlus Real Time PCR System (Applied Biosystems,USA)

•

Taqman® Gene Expression Master Mix Part# 4369016 Lot# 0802023
(Applied Biosystems, USA)

•

Taqman® Gene Expression Assays (Applied Biosystems, USA)

•

Nuclease Free Water (Ambion, USA)

•

Pipetman® p20 Z53746B (Gilson Inc, France)
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•

Pipetman® p200 M10627C (Gilson Inc, France)

•

Pipetman® p1000 E11507C (Gilson Inc, France)

2.6.(ii) Preparation of cDNA Standards for use in the qPCR
Reaction:
For each gene that was amplified by qPCR, a set of standards had to be
amplified for that gene in the same reaction. This resulted in the generation of a
standard curve from which the quantity of the gene expressed in the
experimental samples could be quantified.
The Mouse Universal RNA underwent RT-PCR and the resultant cDNA was
used to generate a set of standards which could be used for each qPCR. One of
the experimental samples was also chosen to generate a second set of standards
that could be used for those genes that have quite low expression – it is best to
pick the experimental sample that is likely to have the highest expression of
your gene of interest.
A standard range of six serial dilutions was selected – such a dilute range
should cover any genes that are abundantly expressed
ST1
100
ng/µl

ST2
10
ng/µl

ST3
1
ng/µl

ST4
0.1
ng/µl

ST5
0.01
ng/µl

ST6
0.001
ng/µl
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Yeast RNA is added to nuclease free water before preparing the standard
dilutions as this prevents very dilute RNA i.e. ST5 and ST6 from sticking to the
tubes.
6µl of 100ng/µl stock of the yeast RNA was pipetted into a fresh 2ml eppendorf
tube containing 594µl of Rnase free water in order to make 1ng/µl dilution of
yeast RNA. 30µl of undiluted standard sample i.e. Universal Mouse cDNA was
pipetted into a fresh tube labelled ST1. 90µl of the RNase free water containing
yeast RNA was pipetted into fresh tubes labelled ST2 to ST6 for a 1:10 serial
dilution. 10µl of ST1 was pipetted into ST2 and mixed. 10µl of ST2 was
pipetted into ST3 and mixed. This was repeated through the remaining
standards until ST6 had been mixed. These six serial dilutions are the set of
standards that will be used in along with each gene that undergoes qPCR in this
study.

2.6.(iii) Preparation of the qPCR Mastermix:
The qPCR mastermix is bought commercially from Applied Biosystems’
Taqman.
The Taqman® Gene Expression Kit and the Taqman® Gene Expression Assays
i.e. the ‘primers and probe’ mix must all be stored on ice. The ‘primers and
probe’ mix must be defrosted and should be wrapped in tin foil as it is
photosensitive.
The number of reactions required to analyse all samples, standards and controls
during one qPCR run was calculated to determine how much master mix must
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be made up. It is important to include extra master mix to account for pipetting
error.
Eg: 50 reactions = 3 RT samples
3 NRT samples (+RNA, H2O instead of RT)
6 standards (Mouse Universal cDNA)
1 RT no RNA (H2O instead of RNA, +RT)
1 NTC (H2O instead of cDNA)
14
x 3 (samples done in triplicate)
42 reactions
+ 8.4 (20% error)
50 reactions

The following qPCR reaction recipe was used for each gene – this recipe
represents the volumes present in one well of the 96 well reaction plate
Taqman Gene Expression Master Mix
Taqman Gene Expression Assay (Specific Primers and Probe)
Rnase free water
cDNA
Total

qPCR
Mastermix
(20µl)

12.5µl
1.25µl
6.25µl
5µl
25µl

2.6.(iv) Preparation of the 96 well qPCR reaction plate:
Accuracy is pivotal to the success of qPCR hence all samples are pipetted in
triplicate using ART pipette tips.
5µl of each standard was pipetted into three wells. 5µl of each cDNA sample
were pipetted into three wells. 5µl of the NTC control was pipetted into one
well. 5µl of the RTnoRNA control was pipetted into one well. 20µl of the qPCR
master mix was then added to each well. The plate was then covered with an
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optical adhesive cover and centrifuged. The plate was wrapped in tin foil and
stored at 4ºC until its analysis on the qPCR machine. The plate was run as on
the Applied Biosystems StepOnePlus Real Time PCR Machine in accordance
with the standard protocol. The qPCR results for each gene were analysed using
the accompanying StepOnePlus software and bar charts were generated to
visualise gene expression.

Fig 2.3: An example of a 96-well plate Excel spreadsheet from the BDNF study. The 96 wells are
replicated in Excel so that it can be used as a map when filling the plate. Each well is named with regards
to the assigned individual sample or standard triplicate. The negative controls RT no RNA and NTC are
also included. WT STD refers to the series of standard dilutions that are used in order to generate the
standard curve for these particular samples. WT refers to the wild-type samples, BDNF+/- refers to the
samples that are conditional for the heterozygous BDNF knockout whilst BDNF-/- refers to those
samples that are homozygous for the conditional BDNF knockout. PRKO samples are those lacking any
PR. qPCR plates set up for other target genes in this project are all based on this template.
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2.7. Detection of the qPCR product on a 1%
agarose gel
6g of agarose powder was added to 6mls of 10X TBE buffer in a conical flask.
1µL of 0.5µg/µl ethidium bromide was also added to the conical flask. The
solution was then made up to 60mls with double distilled water. The agarose gel
solution was then heated for 2 minutes in the microwave to dissolve the agarose
powder. The solution was left to cool for 5 minutes and then poured into the
mould and left to set for 1 hour. 2µL of the loading buffer; TrackIt™
Cyan/Orange Buffer was added to the 25µL DNA sample in the wells of the
qPCR reaction plate. 15µL of the mixture was then loaded onto the gel for
electrophoresis. 10µL TrackIt™ DNA ladder was loaded onto the gel in order to
analyse the size of the qPCR product.

2.8. Statistical Analysis
All qPCR reactions were performed in triplicate. Graphs were generated in
Microsoft Excel and the data was expressed as the fold induction of the mean
values, relative to the wild-type control ± SD. Statistical analysis was carried
out using Analysis ToolPak software and a Student’s t-test was used to
demonstrate the statistical significance of the comparisons that were made
between various sample genotypes and sample treatments. P values less than
0.05 were considered significant.
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3. Project Results:
3.1. qPCR Analysis of Microarray Target Genes:
3.1.(i) The Experimental Cohort for qPCR Analysis of
Microarray Target Genes:
Quantitative PCR analysis was used to determine the expression pattern of the
target genes of interest that had been identified in the microarray. Twelve wildtype mice were selectively bred and treated for this study by a lab technician.
The 12 wild-type mice underwent ovarectomies at 6 weeks of age and were left
to rest for 10 days post surgery. Six of the mice were then selectively treated for
three weeks with a control vehicle and six of the mice were treated with
estrogen and progesterone to again simulate a pregnant proliferative state within
the mammary gland. The treatment consisted of daily subcutaneous injections;
the control treated animals were injected with 50µL of corn oil alone whilst the
hormone treated animals were injected with 50µL of corn oil containing 250ng
of estrogen and 1mg of progesterone. The 12 wild-type mice were sacrificed by
inhalation of CO2 and their mammary glands were surgically removed and
stored at -80ºC. The mouse model may have four or more mammary glands but
for the purpose of this work only one from each was used to generate cDNA for
quantitative PCR. Three additional mice which were homozygous for the
conditional PR knockout were also used; however these samples were in RNA
form and had been archived by the lab at -80ºC for the past three years.
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3.1.(ii) RNA Extraction for the qPCR Analysis of Microarray
Target Genes:
RNA extraction was performed for the 12 mammary glands that were to be
included in the study. Once an RNase free work area had been prepared as per
Materials and Methods 2.2(ii), the mammary glands were homogenised with
Invitrogens Trizol reagent. Trizol maintains the integrity of the RNA while
disrupting cells and dissolving cell components (13). This procedure was carried
out as per Materials and Methods 2.2.(ii). The newly isolated RNA along with
the archived PRKO RNA, was accurately quantified by measuring its
absorbance in a spectrophotometer. The optical density of RNA was measured
at its maximum absorbance wavelength of 260nm. To assess whether any DNA
contamination has occurred during the extraction process, a sample of the
extracted RNA is then electrophoresed on a denaturing agarose gel and stained
with ethidium bromide.
In this study, to further ensure the quality of the extracted RNA, the RNA was
cleaned and purified using a Qiagen RNeasy Mini Kit. This protocol can be
used to purify RNA from enzymatic reactions (e.g., DNase digestion, RNA
labeling) or to desalt RNA samples. Buffer RLT (contains guanidine
thiocyanate) and ethanol are added to the sample to create conditions that
promote selective binding of RNA to the RNeasy membrane. The sample is then
applied to the RNeasy Mini spin column. Total RNA binds to the membrane,
contaminants are efficiently washed away, and high-quality RNA is eluted in
RNase-free water.
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The newly cleaned RNA was once again analysed on the spectrophotometer
(Fig 3.2) and these purer concentrations were used to calculate the volume of
the RNA that would be required for the reverse transcriptase PCR to yield
enough cDNA for the quantitative PCR analysis. All of the RNA samples were
electrophoresed again onto a 0.8% agarose gel. Both the 28S ribosomal RNA
and the 18S ribosomal RNA should appear as two sharp bands.

WTC1

WTC2

WTC3
WTEP1

WTEP2
WTEP3

Figure 3.1: Gel electrophoresis results for the extracted RNA of the 12 wild-type mice. The wild-type
mice have been treated with either a control or with estrogen and progesterone for three weeks. A legend
to identify each lane on the gel is included. The concentrations of these RNA samples were determined
using Beer Lamberts Law (Fig 2.1) and the RNA samples were then pooled together before they
underwent the RT-PCR reaction WTC1, WTC2, WTC3, refer to the names assigned to the pooled wildtype control RNA samples. WTEP1, WTEP2, WTEP3 refer to the names assigned to the pooled RNA
wild-type E&P treated RNA samples. Each pool contains two individual RNA samples.

In order to reduce the work load and accommodate the size restrictions of the
qPCR 96-well plate, the RNA samples were pooled together according to
genotype and treatment. The wild-type control treated RNA samples were
pooled together and the wild-type EP treated samples were pooled together.
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Each pool contained two individual RNA samples and there were a total of three
pools for each treatment group i.e WTC1, WTEP1 (Fig 3.1/3.2). The three
PRKO samples retained their individual sample status as they were the only
samples of this genotype available and for statistical purposes a minimum of
three samples was required.
A Microsoft Excel spreadsheet was designed to calculate the concentration and
volume that was required from each pooled sample to generate a sufficient
amount of cDNA for use in quantitative PCR analysis (Fig 3.2). It was
important to make more than the minimum to ensure that there was enough
cDNA left in case it was needed at a later date for repeat analysis of the data.

Fig3.2: The Excel spreadsheet used to determine the concentration of RNA samples that were to be pooled
together for the RT-PCR reaction. All of the samples had been treated for three weeks with either control or
EP. Six individual wild-type control treated RNA samples were pooled together into three pooled samples
with two individual RNA samples in each (WTC1, WTC2, WTC3). The same was done for the six wildtype EP treated RNA samples (WTEP1, WTEP2, WTEP3). Each pool contains 30µg of RNA, 15µg from
each individual sample. The newly pooled samples undergo spectrophotometry again and the new RNA
concentration µg/µl is determined. 10µg of pooled RNA is required for the RT-PCR reaction, 6µg is
required for the RT sample solution and 4µg is required for the NRT sample solution (Fig2.3) to generate
cDNA for the qPCR analysis.
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3.1.(iii) Reverse-Transcriptase PCR:
Single-stranded cDNA was generated from the total RNA using the Applied
Biosystems High-Capacity cDNA Reverse Transcriptase Kit. The protocol was
carried out as per protocol Materials and Methods 2.5. Negative controls were
set up for this step of the study to ensure that neither the sample nor the reagents
were in any way contaminated. One control consisted of all the RT-PCR
reagents required but did not contain any RNA sample to ensure that none of the
reagents used were contaminated with any genetic material that may be
amplified in the reaction and produce a false positive. The RT-PCR reaction
was also controlled to ensure the integrity and purity of the RNA samples used.
For each RNA sample that underwent the RT-PCR, the same sample was set up
again without the reverse transcriptase enzyme to ensure that any DNA that was
generated was the result of the RT-PCR reaction and not some form of sample
contamination. Once the cDNA had been created, it was stored at 4ºC for
quantitative PCR analysis.

3.1.(iv) Quantitative PCR Analysis (qPCR)
In order to carry out qPCR analysis on the cohort samples, a standard curve had
to be generated against which the samples could be quantified. Mouse Universal
RNA was used to create a standard curve. This RNA was commercially bought
and had a concentration of 1µg/µL. The Universal RNA underwent RT-PCR
alongside the experimental samples, as per Materials and Methods 2.5.(ii), to
produce a final cDNA concentration of 100ng/µl. Six serial dilutions were then
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made from the Mouse Universal RNA and the standard curve was made as per
Materials and Methods 2.6.(ii). In order for a standard curve to be accepted, the
slope of the curve had to be 3.3 ± 0.5 (Fig3.3).

Figure 3.3: A standard curve generated using the Applied Biosystems SDSShell qPCR
software. This curve incorporates four serial dilutions of the Mouse Universal RNA and has an
acceptable slope of -3.26. This particular standard curve was generated for qPCR analysis of
18S, the housekeeping gene that was used in all the qPCR analysis performed in this project.
18S was used to normalise the target genes analysed

The qPCR reagent mastermix and the cDNA samples for the 96 well PCR plate
were set up for each gene as per Materials and Methods 2.6.(iv). Taqman
reagents were used for the reaction and were all commercially bought from
Applied Biosystems. To reduce the effects of human pipetting error, each cDNA
sample was analysed in triplicate on the PCR plate (Fig 3.4).
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Figure 3.4: An Applied Biosystems SDSShell qPCR 96-well plate template. qPCR analysis on the RNA
samples were performed in triplicate and are represented as the small red squares. Well positions 1 -12
account for the standards whilst positions 59 and 60 as well as 71 and 72 account for negative controls.

The quantification of gene targets in this study used the relative quantification
comparative method. The relative target quantity was measured in relation to
standard curves of both standard and reference. A housekeeping gene known as
18S is highly expressed in all cells and it was quantified in each of the cDNA
target samples to be used as an internal endogenous standard against which the
target gene could be normalised. 18S can be referred to as an active reference as
its use can determine changes in the amount of a given sample relative to
another internal sample (Lanz, 2008).

3.1.(v) qPCR Analysis of the Microarray Target Genes:
The target genes RANKL, Wnt4 and Amphiregulin are three well established
genes with regards to mammary gland literature. The microarray carried out by
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the lab, showed that all three genes were upregulated following E&P treatment
for three weeks in the wild-type mouse model. Incidentally, the same three
genes were all downregulated in the PRKO mice following the same treatment,
suggesting that these genes are targets of the progesterone signalling pathway in
the mammary gland and may be the paracrine factors responsible for the cellular
proliferation in steroid receptor negative cells. Therefore it was of interest to
confirm the microarray and study the mRNA expression after three weeks of
E&P treatment to determine whether the genes were still regulated at what is
essentially day 12.5 of pregnancy. The qPCR protocols as per Materials and
Methods 2.6. were employed to analyse gene expression within the mammary
gland.

3.1.(vi) Proliferative Mediators of the Progesterone Response:
RANKL:
RANKL is known to have a role in mammary gland development during
pregnancy. RANKL is thought to co-localise with progesterone receptors in
response to pregnancy levels of estrogen and progesterone. RANKL is absent in
the virgin gland, it is upregulated during pregnancy and decreases after day 18.5
of a murine pregnancy (Gonzales-Suarez et al, 2007). Their experiments also
show that the highest levels of RANKLs ligand; RANK correlates with the peak
of mammary epithelial proliferation at day 15.5 of pregnancy (10). In this study,
RANKL mRNA levels were analysed after 21 days of estrogen and

87

progesterone treatment to observe its expression at this simulated late stage of
pregnancy and proliferation (Fig 3.5).

Fold Induction of
RANKL mRNA
Expression

Regulation of the Proliferative Mediator RANKL mRNA by the
Progesterone Receptor in the Pregnant Mammary Gland

*

16
14
12
10
8
6
4
2
0
Wild-Type
Control Treated

P < 0.01

Wild-Type
E&P Treated

PR -/E&P Treated

Sample Type and Genotype

Figure 3.5: Quantitative PCR analysis of RANKL mRNA expression in wild-type and conditional PR-/mice which have been either control treated or treated with estrogen and progesterone for three weeks in
order to simulate a pregnant murine state. Gene expression is analysed in terms of fold induction relative to
the wild-type control and error is assessed by standard deviation. The upregulation of RANKL mRNA in
the wild-type E&P sample is significant when compared to the wild-type control sample as determined by a
paired Student’s t-test *(p<0.01). Statistically significant downregulation of RANKL mRNA is also seen in
the conditional PR-/- treated sample when compared to the wild-type E&P treated sample where p<0.01.

The results in fig 3.5 show a 12-fold increase in RANKL mRNA expression
when treated with estrogen and progesterone for three weeks. Statistical analysis
confirms that this increased induction of RANKL is statistically significant (p<
0.01). There is a significant difference between the wild-type E&P-treated
samples and the PRKO samples (p<0.01) thus suggesting that RANKL
expression in the E&P-treated mammary gland is strongly dependent upon
progesterone. From this data set, it can be inferred that RANKL has an active
and functioning role to play in the late stages of pregnancy where there is
intense growth and proliferation due to the its upregulation during this time.
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Wnt4:
Wnt4 is a secreted glycoprotein which is coexpressed in PR positive cells and is
essential for regulating ductal branching via paracrine mechanisms of
proliferation (Conneely et al, 2001). Wnt4 upregulates the activity of its target
β-catenin which is hypothesised to have a role in cell fate decisions in the
mammary gland. The paracrine action of Wnt4 has been said to occur earlier in
pregnancy than that of RANKL. Wnt4 expression was analysed in this study
after three weeks of the E&P treatment in order to assess the strength of its
signalling abilities at this later stage of pregnancy.

Fold Induction of Wnt4
mRNA Expression

The Regulation of the Proliferative Mediator Wnt4 mRNA by the
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Figure 3.6: Quantitative PCR analysis of Wnt4 mRNA expression in wild-type and PR-/- mice which have
been either control treated or treated with estrogen and progesterone for three weeks in order to simulate a
pregnant murine state. Gene expression is analysed in terms of fold induction relative to the wild-type
control and error is assessed by standard deviation. The data was analysed using a paired Student’s t-test
and statistically significant downregulation of Wnt4 mRNA (p<0.01) by PR was observed when the EPtreated wild-type samples were compared to the PRKO EP-treated samples.

Figure 3.6 shows that Wnt4 mRNA expression is only slightly upregulated in
the E&P treated wild-type when compared to the wild-type control model which
correlates with the previous microarray data, however statistical analysis of the
data has shown that this increase is not significant thus suggesting that at day
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12.5 of pregnancy, there seems to be no significant increase in the activity of
Wnt4. This data set does seem to concur with the suggested early role of Wnt4
action in mammary gland development. At what is presumed to be ~day 12.5 of
pregnancy-associated proliferation, it is likely that Wnt 4 activity levels may
have already peaked therefore this data set may be showing Wnt4
downregulation possibly induced by some kind of a negative feedback
mechanism. Knockout models of Wnt4 have shown that the consequences of its
absence fade in late pregnancy therefore other parallel pathways may begin to
contribute thus allowing Wnt4 levels to drop off and return to normal (Sternlicht
et al, 2006). The PRKO sample does confirm the regulation of Wnt4 mRNA by
the progesterone receptor as Wnt4 mRNA is further reduced by 0.8 fold in the
absence of PR compared to the wild-type EP-treated samples and this
downregulation is shown to be statistically significant (P<0.01). The results
show that there is still some Wnt4 mRNA present in the PRKO samples but it is
possible that this is due to the cooperative regulatory powers of prolactin
signalling.

Amphiregulin:
Amphiregulin is best documented in terms of pubertal mammary gland
development where estrogen is the primary regulating hormone however since it
was shown to be strongly regulated by progesterone in the microarray (Fig
1.10), its expression mRNA levels during the intense period of pregnancyassociated growth and proliferation were deemed to be worthy of further
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analysis. This study wanted to assess the potential of Amphiregulin alongside
RANKL and Wnt4 as another paracrine mediator of progesterone signalling
during late pregnancy.
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Figure 3.7: Quantitative PCR analysis of Amphiregulin mRNA expression in wild-type and PR-/- mice
which have been either control treated or treated with estrogen and progesterone for three weeks in order
to simulate a pregnant murine state. Gene expression is analysed in terms of fold induction relative to the
wild-type control and error is assessed by standard deviation. Amphiregulin mRNA is significantly
upregulated (*p<0.01) in the wild-type mouse upon treatment with EP for three weeks, when compared
to the wild-type control samples. Amphiregulin is significantly downregulated (p<0.01) in the absence of
PR as determined by the 10 fold downregulation of Amphiregulin mRNA in the PRKO sample. The
PRKO samples was also treated for three weeks with EP and statistical analysis was determined with a

Amphiregulin mRNA expression exhibits a 13-fold increase in activity
compared to its wild-type control treated expression. This upregulation induced
by the hormonal treatment is deemed statistically significant (p<0.01). The
results in figure 3.7 do suggest that Amphiregulin is a transcriptional target of
the progesterone receptor as its expression in the EP treated sample is
downregulated by 10-fold when PR is ablated. The difference between
Amphiregulin mRNA expression in the wild-type EP-treated sample and the
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PRKO sample is also statistically significant as determined by the student’s ttest (p < 0.01). However, Amphiregulin’s expression in the absence of PRKO is
still greater than that in the control model when treated with E&P thus it is most
likely that Amphiregulin is still regulated by estrogen to some extent which
accounts for the retained activity.

Elf5:
Elf5 is a transcription factor that signals downstream of the prolactin receptor.
Its expression is highly upregulated during pregnancy and is thought to have
significant implications for alveolar morphogenesis in the mammary gland.
Since progesterone and prolactin signalling pathways can often cooperate and
even converge downstream of their respective receptors, it is not unlikely that
progesterone could exert some effect on Elf5 mRNA expression thus qPCR
analysis was carried out on the Elf5 gene for this study.
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Figure 3.8: Quantitative PCR analysis of Elf5 mRNA expression in wild-type and PR-/- mice which
have been either control treated or treated with estrogen and progesterone for three weeks in order to
simulate a pregnant murine state. Gene expression is analysed in terms of fold induction relative to the
wild-type control and error is assessed by standard deviation. Elf5 mRNA expression is significantly
upregulated in wild-type mice upon treatment with EP for three weeks when compared to the control
treated wild-type mice (*p<0,01). In EP-treated wild-type mice, Elf5 is also significantly downregulated
(p<0.01) when PR is ablated in the PRKO sample thus suggesting that Elf5 is strongly regulated by PR.
Statistical analysis was determined by a paired Student’s t-test.
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In figure 3.8, Elf5 mRNA expression is significantly raised during a simulated
pregnant state; it has an 8-fold increase when compared to the wild-type control
(p<0.01). Elf5 mRNA also shows strong regulation by the progesterone receptor
at this stage of pregnancy as evidenced by the Elf5 mRNA levels measured in
the PRKO sample. There is a strong and statistically significant decrease in Elf5
mRNA expression between the wild-type EP-treated samples and the PRKO
EP-treated samples. This seems to suggest a lack of compensation from the
prolactin signalling cascade in terms of Elf5 regulation.

3.1.(vii) Anti Proliferative Mediators of the Progesterone
Response:
For the purpose of this study, it is important to consider the role that the
progesterone receptor may play in controlling the expression of genes that are
known to inhibit the proliferative signals which produce much of the ductal
branching and alveolar differentiation associated with pregnancy.

TGF-β1:
TGF-β1 has been identified as a negative regulator of branching morphogenesis
in the mammary gland. TGF-β1 deficient mice exhibit significantly accelerated
but morphologically normal ductal development. It has been hypothesised that
TGF-β1 may aid in the maintenance of proper ductal spacing by enabling
neighbouring ducts to avoid one another (Sternlicht et al, 2006).
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There is a significant difference between TGF-β1 mRNA levels in the control
and EP-treated wild-type samples. TGF-β1 mRNA expression is decreased (0.4
fold) during the simulated late pregnancy model when compared to the wildtype control (p<0.01) (Figure 3.9).
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Figure 3.9: Quantitative PCR analysis of TGF-β1 mRNA expression in wild-type and PR-/- mice which have
been either control treated or treated with estrogen and progesterone for three weeks in order to simulate a
pregnant murine state. Gene expression is analysed in terms of fold induction relative to the wild-type control
and error is assessed by standard deviation. The Student’s t-test is used to determine the statistical significance
of these results when p < 0.01. TGF- β1 is significantly downregulated in the wild-type samples upon
treatment with EP for three weeks (*p<0.01). TGF- β1 also demonstrates significant upregulation (p<0.01) by
progesterone as its expression increases again in the EP-treated PRKO samples where PR is absent when
compared to the EP treated wild-type samples.

This data concurs with the reports that TGF-β1 activity falls during mid- to late
pregnancy. The activity of TGF-β1 may have an earlier transcriptional response
to the increased proliferative state induced by pregnancy and so its stronger
effects may occur prior to this later stage of the pregnant mouse model. It
should be also noted that at the time point of this data set, TGF-β1 mRNA
expression also exhibits significant regulation by the PR, which is demonstrated
in the PRKO samples where TGF- β1 mRNA expression increases again to
mimic wild-type control expression levels thus suggesting that progesterone
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seems to negatively regulate TGF- β1 to minimise its effects during such a
proliferative phase of pregnancy within the mammary gland.

TGF-β2
In a system as complex as the mammary gland, it may be difficult to discern the
intermediaries in the transduction pathway therefore as a point of interest, qPCR
analysis was also performed on TGF-β2, another TGF-β family member. TGFβ2 expression was shown to be low in the virgin gland; it increases linearly
through pregnancy, begins to fall at day 17 of pregnancy and decreases through
lactation (Monks et al, 2007).
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Figure 3.10: Quantitative PCR analysis of TGF-β2 expression in wild-type and PR-/- mice which have
been either control treated or treated with estrogen and progesterone for three weeks in order to
simulate a pregnant murine state. Gene expression is analysed in terms of fold induction relative to the
wild-type control and error is assessed by standard deviation. The data was analysed for statistical
significance using a student’s t-test however no comparisons made between these samples were
deemed statistically significant when p < 0.01 nor when p < 0.05. The larger error bar on the EPtreated wild-type samples makes statistical analysis more difficult.

The profile for TGF-β2 showed a slight increase in TGF-β2 mRNA expression
in the wild-type following treatment with E&P for three weeks. If TGF-β2 is

95

only supposed to be decreasing after day 17 of pregnancy, then it is likely that at
day ~12.5 of the simulated pregnancy, TGF-β2 would still be increasing
compared to the wild-type control as it is a thought to be a more prominent
marker in late stage pregnancy than TGF-β1. The TGF-β2 results show no
significant regulation by the progesterone receptor upon treatment with EP (Fig
3.10). Its expression in the absence of progesterone is almost the same as its
expression in the wild-type counterpart which suggests that there is no
regulation by progesterone occurring at this time point. It could be possible that
TGF-β2 is an estrogen regulated gene which may explain its upregulation upon
EP treatment. Statistical analysis of this data set in Fig 3.10 showed that none of
these results were statistically significant.

Mig6 and Sfrp2:
Another form of anti-proliferative regulation is carried out by the progesterone
receptor which was investigated during the course of this study. It is thought
that PR contributes to the normal development and proliferation of the pregnant
mammary gland by downregulating the anti-proliferative factors which are
capable of inhibiting the effects of progesterone. The progesterone receptor acts
to target the inhibitors of two of its strongest paracrine proliferative factors.
Mig6 and Sfrp2 are the two anti-proliferative factors that were examined. Mig6
is a known inhibitor of the epidermal growth factor receptor (EGFR) which is
the receptor that Amphiregulin signals through and Mig6 appears to be
downregulated in response to progesterone.
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Sfrp2 is the second anti proliferative factor that was observed, it is an inhibitor
of the Wnt signalling pathway hence it would be expected to be decreased
during times of proliferation so as to allow proliferative signalling of
progesterone via Wnt4.
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Figure 3.11: Quantitative PCR analysis of Mig6 mRNA expression in wild-type and PR-/- mice which
have been either control treated or treated with estrogen and progesterone for three weeks in order to
simulate a pregnant murine state. Gene expression is analysed in terms of fold induction relative to the wildtype control and error is assessed by standard deviation. Statistically significant regulation is determined by
a Student’s t-test and noted by the presence of p-values when p < 0.05.
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Figure 3.12: Quantitative PCR analysis of Sfrp2 mRNA expression in wild-type and PR-/- mice which
have been either control treated or treated with estrogen and progesterone for three weeks in order to
simulate a pregnant murine state. Gene expression is analysed in terms of fold induction relative to the
wild-type control and error is assessed by standard deviation. The data has been analysed using a
student’s t-test and deemed statistically significant by the presence of p-values when p < 0.01
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cDNA from the same cohort as the previous proliferative signals was used to
assess the expression of Mig6 and Sfrp2 after three weeks of E&P treatment.
The results show that after three weeks of treatment, the gene expression
profiles for both genes are remarkably similar. There is an approximate 2-fold
increase in mRNA expression of the E&P treated wild-type model when
compared to the wild-type control which suggests that the anti-proliferative
genes are increasing at this late stage of pregnancy. Mig6 mRNA shows
significant upregulation (p<0.05) in Fig 3.11 whilst Sfrp2 exhibits more of a
significant difference in Fig 3.12 (p<0.01). However, there seems to be no
significant regulation of either of the genes at this time point by the
progesterone receptor which is indicated by the mRNA levels observed in the
PRKO samples. It seems unlikely that progesterone action is directly
responsible for the increase of these genes in the simulated pregnant state since
their expression profiles are hardly changed in its absence when compared to
the wild-type EP treated samples.
It is important to mention that other qPCR analysis was carried out throughout
this study which analysed the anti proliferative genes, Mig6 and Sfrp2 after 48
hours of treatment with estrogen and progesterone as opposed to the current
three week treatment period (Fig 3.13, 3.14).
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Figure 3.13: Quantitative PCR analysis of Mig6 mRNA expression in wild-type mice which have
been either control treated, treated with E&P, treated with E alone or treated with P alone for 48 hours
to determine if they exhibit an early transcriptional response to the ovarian steroid hormones. Gene
expression is analysed in terms of fold induction relative to the wild-type control and error is assessed
by standard deviation. The data has been analysed using a student’s t-test and deemed statistically
significant; * p < 0.01
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Figure 3.14: Quantitative PCR analysis of Sfrp2 mRNA expression in wild-type mice which have
been either control treated, treated with E&P, treated with E alone or treated with P alone for 48 hours
to determine if they exhibit an early transcriptional response to the ovarian steroid hormones. Gene
expression is analysed in terms of fold induction relative to the wild-type control and error is assessed
by standard deviation. The data has been analysed using a student’s t-test and deemed statistically
significant; ** p < 0.05, *p<0.01

The data sets obtained showed that the E&P treated wild-type mice had
significant downregulation of both anti-proliferative genes when compared to
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the wild-type control mice. Unfortunately there was no PR knockout sample to
accompany these data sets and confirm that it is progesterone that is specifically
inducing their downregulation therefore any inference made on their part is
considered negligible in terms of statistical significance.

3.2. The BDNF Study: A Novel Target of
Progesterone Signalling in Pregnancy-Associated
Mammary Gland Development
These results address the novel target gene BDNF with a view to proving its
hypothesised function in the mammary gland which was proposed in section
1.7(iii). Previous investigations were carried out on this gene (Fig 1.13 / Fig
1.15) which encouraged the lab to invest in BDNF knockout mouse models to
further their research in this area. Mammary gland tissue from these BDNF
knockout mouse models were used to generate experimental data for this section
of results.
Since the previous study had shown the established signals of proliferation;
RANKL (Fig 3.5), Wnt4 (Fig 3.6) and Amphiregulin (Fig 3.7), to be
functionally active at the same developmental time point, these signals were
suitable targets to be measured in the BDNF knockout models to validate the
hypothesised role of BDNF. The expression of all three proliferative signals
were analysed in terms of a wild-type control sample, a wild-type hormonetreated sample, a BDNF heterozygous hormone-treated sample and also a
BDNF homozygous hormone-treated sample. The data sets produced following
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the quantitative analysis of each proliferative target proved to be very similar in
their respective expression patterns (Fig 3.18).

3.2.(i) The BDNF Experimental Cohort:
The CRE-loxBDNF gene targeting approach was used in order to specifically
ablate expression of BDNF in the mammary glands of C55/129 mice. All of the
transgenic techniques and breeding were carried out at the in-house Baylor
College of Medicine Animal Facility. A cohort of mice was once again selected
from these animals to accommodate the genotyping requirements for this
experiment. Twenty-seven mice were used in total to produce the BDNF data
sets. For this study, there were twelve wild-type mice, seven mice which were
heterozygous for the conditional BDNF knockout and eight mice which were
homozygous for the conditional BDNF. The mice all underwent ovarectomies
and after ten days of rest, they were treated with either control or with estrogen
and progesterone for three weeks in the same manner as the animals involved in
the previous study outlined in section 3.1(i). After a period of treatment, the
mice were all sacrificed using CO2 and their tissues of interest were surgically
removed and frozen at -80ºC.

3.2.(ii) Techniques of the BDNF Study:
The mammary glands from the BDNF study were all treated in the same manner
as the mammary glands previously dealt with in section 3.1. The techniques
were all carried out in an identical fashion, from RNA extraction to reverse
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transcriptase PCR to quantitative PCR analysis. The BDNF study does not
include a PRKO sample as all of the targets which were analysed using the
BDNF knockouts have already been analysed in terms of the PRKO sample in
the PR study therefore this expression pattern was not repeated here. Once the
cDNA was generated from the extracted RNA, selected gene targets could be
amplified within each sample.

A:

B:

Figure 3.16: (A) Agarose gel electrophoresis
results for the extracted RNA of the 27 wildtype and BDNF knockout mice. The mice
have been treated with either a control or
with estrogen and progesterone for three
weeks. (B) A legend to identify each lane on
the gel is included.

3.2.(iii) Proliferative Mediators of Progesterone in BDNF
Knockout Mammary Gland Tissue:
The hypothesis suggests that the secreted BDNF protein acts in the mammary
gland under the control of PR, to curb the proliferation induced by the major
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proliferative signals and by doing this aids in maintaining the proper spacing
and structure of the ductal branching networks as they grow within the
mammary gland. The data sets obtained using BDNF conditional heterozygous
and homozygous knockout mouse models suggest concurrence with the
proposed hypothesis (Fig 3.18).

Progesterone

Progesterone Receptor

Progesterone Response Element

Upregulation of Progesterone Target Genes

RANKL
Wnt4
Amphiregulin

Increases ductal branching
Increases alveolar differentiation

BDNF

Curbs / limits the effects of
RANKL, Wnt4 and
Amphiregulin

Fig 3.17: Schematic flowchart of the Conneely hypothesis of BDNF regulation by PR and its
functional role with regards to controlling the proliferative genes to maintain normal mammary gland
development

103

Previous qPCR results for the proliferative signals RANKL, Wnt4 and
Amphiregulin (Fig 3.5- 3.7), following PR ablation showed dramatic
downregulation of their expression. However in the qPCR data presented in Fig
3.18 below; the expression of these proliferating genes is maintained in the
partial or complete absence of BDNF, thus their expression and proliferation
continues to be promoted thus causing the hyperbranching phenotype. Whilst
the qPCR data does not provide any definitive evidence of how BDNF may be
working in the mammary gland, this data infers that BDNF does not directly
regulate the proliferative signals but that its absence does indeed produce a
hyperbranching which is most likely caused by the uncontrolled activity of the
major proliferative signals that are known to be operating in the gland at this
time point. The statistical analysis also supports this statement as there were no
statistical differences observed between the EP-treated wild-type samples and
the EP-treated BDNF knockout models for all three target genes. Amphiregulin
and RANKL did exhibit significant upregulation in the wild-type EP-treated
samples when their expression was compared to those observed in their wildtype control counterpart samples, this was also observed in the previous study
(Fig 3.5 and 3.6).
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Regulation of the Proliferative Signal Amphiregulin mRNA by
BDNF in the Pregnant Mammary Gland
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Figure 3.18: Quantitative PCR analysis of (A) Amphiregulin, (B) RANKL and (C) WNT4 expression in
wild-type, BDNF+/- and BDNF-/- mice which have been either control treated or treated with estrogen and
progesterone for three weeks in order to simulate a pregnant murine state. Gene expression is analysed in
terms of fold induction relative to the wild-type control and error is assessed by standard deviation. Statistical
significance is noted by the presence of p- values; *p<0.01. Figure 3.18A exhibits a significant difference
between the wild-type control samples and the upregulation of the EP-treated samples .Just like figure 3.18A,
figure 3.18B exhibits a significant difference between the wild-type control samples and the upregulation of
the EP-treated samples however 3.18C has no statistical differences between any of the samples analysed.
There was no significant difference between the wild-type EP treated samples and both of the BDNF knockout
samples

105

Figure 3.18A and 3.18B suggest that Amphiregulin and RANKL may be
regulated more strongly than Wnt4 (Fig 3.18C), as Wnt4 showed no significant
statistical differences between its differentially treated wild-type expression
profiles. It is important to note the absence of any significant p-values for any of
the three targets when their induction in the EP-treated wild-type samples was
compared their induction in both of the conditional BDNF knockout samples
which were also EP-treated. This lack of statistical significance seems to
correspond with our hypothesised role of BDNF in the mammary gland in that
the absence of BDNF allows the proliferative signals to continue supporting
growth and differentiation in the mammary gland. There was no statistical
significance for the three genes noted between the expression profiles induced
in the heterozygous BDNF knockout model and those induced in the
homozygous BDNF knockout model. This may suggest that a partial BDNF
knockout may incur the same consequences as a total knockout in the mammary
gland however such a conclusion would require much more detailed
investigation.

3.2.(iv) Additional qPCR Analysis of BDNF Function:
Another qPCR data set that was produced for BDNF examined BDNF mRNA
expression at an early treatment time of 48 hours. This small experiment looked
at BDNF expression in wild-type mice only which were differentially treated
with hormones for 48 hours only. The mice were treated with either control,
E&P, P alone or E alone. The purpose of this work was to examine how BDNF
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was being regulated at an earlier stage of proliferation within the mammary
gland and so the treatment time was scaled back to reflect this. This experiment
only used wild-type mice as it was performed simply a preliminary enquiry into
BDNF activity and its results can not carry much weight due to the absence of
the PRKO sample form this data set. Due to breeding difficulties, no PRKO

Fold Induction of
BDNF mRNA expression

were available within the time frame of this experiment.
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Fig 3.19: Quantitative PCR analysis of BDNF expression in wild-type mice which have been either control
treated, treated with estrogen and progesterone, treated with estrogen alone or treated with progesterone alone
for 48 hours in order to assess early transcriptional regulation of BDNF. Gene expression is analysed in terms
of fold induction relative to the wild-type control and error is assessed by standard deviation. A student’s t-test
was performed in order to assess the statistical significance of the results obtained. In the case of this data set,
no regulation of any statistical significance could be reported.

However, the 48 hour data infers that BDNF does have an early transcriptional
response to E&P treatment. No real upregulation of transcription is observed
when treated with either of the hormones alone which would suggest that the
role of BDNF again seems to be pregnancy-associated mammary gland
development. BDNF does seem to have a PRE sequence therefore it is expected
that its expression would increase directly upon treatment with P yet this did not
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occur at 48 hours. It is important to note that due to the large error bar on the
wild-type EP-treated sample in figure 3.19, no statistical significance can be
applied to this set of BDNF results.

3.3. Progesterone Regulated Target Genes of the
Uterus
The third and final study in this project incorporated work on the uterus with a
view to comparing progesterone signalling between it and the mammary gland.
The uterus was of particular interest with regards to progesterone signalling due
to the contrasting effects it elicits in both tissues. Just as progesterone was
observed in the mammary gland at a particular time-point, i.e. after three weeks
of E&P treatment, the uterus was also subjected to a particular course of
treatment which emphasised the point during reproduction that progesterone is
most potent in its uterine actions. The mouse models used for the uterine
investigations were treated with progesterone alone for six hours progesterone is
thought to prime the endometrium for implantation of the blastocyst in the early
stages of pregnancy.
qPCR technology is employed to compare genes analysed in the uterus to those
already analysed in the mammary gland. Some other more uterine-specific
progesterone regulated genes were also analysed using qPCR to better gauge the
effects that progesterone is stimulating in a differing reproductive environment
to the mammary gland.
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3.3.(i) The Experimental Cohort for the Uterus Study:
For the preparation of uteri samples in this study, thirty-five C55/129 mice were
used in this uterine study. Eight wild-type control mice were used along with
various PR knockout mouse models of varying genotype. The following PR
genotypes used in this study were all treated with progesterone only for 6 hours.
These genotypes included nine wild-type mice, nine PR isoform A knockout
mice (PRAKO), five PR isoform B knockout mice (PRBKO), four PR knockout
(PRKO) mice and three PR heterozygous knockout (PRKO+/-) mice. As with
the previous cohorts of mice, all of these mice were weaned at three weeks,
underwent ovarectomies and were allowed to rest for ten days before the
administration of treatment. Treatment for this cohort consisted of a single
subcutaneous injection of 1mg of progesterone; the mice were then sacrificed
six hours later. This acute form of treatment serves to upregulate the expression
of any rapidly induced genes that are regulated by progesterone within the
uterus. It is these genes that are of interest to this study as they are the genes
most likely to partake in the decidualisation reaction during the periimplantation
period of pregnancy. Preparing for implantation is the most critical role of
progesterone in the uterus therefore analysing various genes at this time point
may infer which, are the major mediators of progesterone action.
It should be noted that the uterine cohort includes PRAKO and PRBKO samples
which were not included in the other studies due to breeding difficulties with
various mice and also due to the questionable integrity of some of the archived
samples. Unfortunately one of the three PRKO+/- samples was wrongly labelled
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as a PRAKO+/- when the genotyping records were checked and was therefore
unable to be included in the study. Since there were only two PRKO+/- samples
remaining, they also had to be excluded as error bars could not be generated for
any data produced by them. Nevertheless, the use of PRAKO and PRBKO in
the uterus study enables much more information to be gathered from the qPCR
analysis with regards to the mechanisms of progesterone regulation for each
target gene.

3.3.(ii) RNA Extraction for the Uterus Study:
Once the animals were sacrificed, their uteri were frozen at -80ºC for RNA
extraction. Only one horn of the uterus was used from each animal for RNA
extraction. The frozen uteri were thawed and homogenised in Trizol just as the
mammary gland tissues were. The RNA was extracted as before and analysed
for quality and purity (Fig 3.20). To accommodate the size limitations of the
qPCR plate, the extracted RNA of these individual mice were then pooled
within their genotypes to make two or three pooled samples in a manner similar
to Fig 3.2. The concentrations of these newly pooled samples was determined
and it was on these ’pooled’ genotypes that the gene expression assays were
performed

110

Fig 3.20: (A) Agarose gel electrophoresis results for the extracted RNA of the 31 wild-type mice.
The wild-type mice have been treated with either a control or with progesterone alone for 6 hours.
(B) A legend to identify each lane on the gel is included

3.3.(iii) Techniques of the Uterus Study:
Reverse-transcriptase PCR was carried out on the pooled RNA samples as per
Materials and Methods 2.5 and cDNA was generated successfully and stored at
4ºC for quantitative PCR analysis. The qPCR techniques were carried out as per
Materials and Methods 2.6 in the same manner for the uterus samples as they
had been for the previous mammary samples. The calculations were made for
each reaction and qPCR Excel templates were designed for the analysis of each
target gene. Each uterus sample had an NRT negative control sample as well
which was included in every reaction. The NTC and the RTnoRNA negative
controls were also included in PCR reactions to ensure no contaminations had
occurred throughout the experimental preparations. Universal mouse RNA was
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also used as the standard to generate the standard curve for the uterus qPCR
reactions. Again 18S was used as the normalising gene for the study.

Fig 3.21: A logarithmic plot from the qPCR analysis of 18S expression in the uterus samples. The
negative controls are the samples expressed to the far right of the graph. The threshold value is
represented by the blue line.

3.3.(iv) The Comparative Uterus Target Genes:
The first three targets which were selected for analysis in the uterus were
Amphiregulin, Wnt4 and RANKL. Since qPCR had been successfully
performed on these targets in the other studies, they became ideal candidates for
a comparative study with the uterus. Amphiregulin and Wnt4 are quite well
published with regards to a functional role in the uterus however less is known
about RANKL but its uterine expression was analysed nevertheless.
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Amphiregulin:
Amphiregulin is a well established target of progesterone signalling and this is
reflected in the uterus as well as in the mammary gland. Amphiregulin is
expressed in the luminal epithelium of the uterus and its expression after six
hours of treatment suggests that it has a functional role to play in the
implantation of the embryo into the stroma. PR is mostly localised to the
stromal cells of the uterus however it could once again employs paracrine action
to upregulate Amphiregulin. The Amphiregulin data set shows very strong ( a
120-fold induction) and statistically significant upregulation of gene expression
in the wild-type models upon treatment with P (Fig 3.22). There seems to be
total progesterone-dependent regulation of the gene after six hours of Ptreatment as is inferred by the drastic downregulation of Amphiregulin in the
PRKO sample when compared to the wild-type P-treated sample.

Fold Induction of
Amphiregulin mRNA
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Amphiregulin mRNA expression in the uterus of wild-type mice
and mice with varying PR genotypes that have been treated
with P for 6 hours
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Fig 3.22: qPCR analysis of Amphiregulin mRNA expression in the uterus of wild-type mice, PRAKO,
PRBKO, PRKO mice that have either been treated with control or treated with progesterone for six
hours. Gene expression is analysed in terms of fold induction relative to the wild-type control and error
is assessed by standard deviation. A Student’s t-test was used to statistically analyse the data where *:p
< 0.01 was deemed to be significant. There was significant upregulation of Amphiregulin in the wildtype samples after treatment with P for six hours (*;p<0.01). Amphiregulin then shows further
statistically significant behaviour in the wild-type P-treated samples; it is significantly downregulated
when the PR-A isoform is selectively ablated and also when there is a total knockout of PR in the
PRKO samples (p<0.01). There is downregulation of Amphiregulin in the PRBKO samples too but this
is less significant than that observed in the other comparisons.
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The statistics show that there is a significant regulation of Amphiregulin by PRA upon treatment with P as its expression is obviously downregulated in the
absence of PR-A thus PR-A seems to be the dominant receptor for
Amphiregulin signalling in the uterus (Fig 3.22). There is also downregulation
of Amphiregulin seen in the absence of PR-B after the six hour treatment. This
is not as significant as the decrease observed in the PRAKO sample;
nevertheless P-B does seem to be supporting the role of PR-A in mediating
Amphiregulin expression.

Wnt4:
Wnt4 is stated as being expressed in the endometrial stromal cells and is thought
to increase during the decidualisation reaction. Wnt4 is strongly regulated by P
in the mammary gland but this regulation does not seem to translate to the
uterus (Fig 3.23). The data presented by the qPCR analysis shows an increase in
Wnt4 activity in the uterus of the wild-type mice after a six hour treatment of P.
Whilst the fold induction is not as large as that seen for Amphiregulin in Fig
3.22, the increase is still considered statistically significant (p<0,01). No results
of any statistical significance can be recognised with regards to the regulation of
Wnt4 by progesterone when the P-treated wild-type samples were compared to
the other P-treated samples of varying PR genotype.
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Fold Induction of
Wnt4 Expression

Wnt4 expression in the uterus of Wild-Type mice and mice with
varying Progesterone Receptor (PR) genotypes that have
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Fig 3.23: : qPCR analysis of Wnt4 expression in the uterus of wild-type mice, PRAKO, PRBKO, PRKO
mice that have either been treated with control or treated with progesterone for six hours. Gene expression
is analysed in terms of fold induction relative to the wild-type control and error is assessed by standard
deviation. A student t-test was used to statistically analyse the data where *; p < 0.01 was deemed to be
significant. Wnt4 expression is significantly upregulated in the wild-type sample after a six hour treatment
of progesterone when compared to the wild-type control however none of the EP-treated samples show any
significant regulation with regards to the various PR isoform knockouts.

Any regulation of Wnt4 by progesterone in the uterus is certainly not as clear as
the regulation observed in the case of Amphiregulin. Wnt4 has a differing
expression profile in the PRKO uterus samples when compared to that already
seen in the PRKO mammary gland samples (Fig 3.6) however the literature
states that in the uterus Wnt4 operates as a downstream target of BMP2 which
itself is regulated by progesterone therefore this could go some way to
explaining the lack of regulation seen at 6 hours. It could be possible that Wnt4
is too far downstream in the progesterone signalling pathway to be classed as a
rapidly induced gene.
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RANKL:
RANKL has been established as an important proliferative and differentiating
signal in the mammary gland therefore it was feasible that RANKL may also
participate in the proliferation and differentiation that occurs in the uterus
during the periimplantation period. RANKL does not exhibit any more
significant regulation by progesterone than Wnt4 did, its mRNA uterine
expression profile is also not as strong as that observed in the mammary gland.

Fold Induction of
RANKL m RNA
E xpression

RANKL mRNA expression in the uterus of Wild-Type mice and
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Fig 3.24: qPCR analysis of RANKL expression in the uterus of wild-type mice, PRAKO, PRBKO, PRKO
mice that have either been treated with control or treated with progesterone for six hours. Gene expression is
analysed in terms of fold induction relative to the wild-type control and error is assessed by standard
deviation. A student t-test was used to statistically analyse the data where p < 0.01 was deemed to be
significant. The data set produced by the analysis of RANKL contains no results of such statistical
significance however the upregulation of RANKL in the wild-type samples following treatment is significant
when **;p < 0.05 which suggests some increased uterine activity for RANKL based on this six hour treatment.

Also RANKL is expressed in the epithelial cells of the mammary gland whereas
whilst RANKL is clearly expressed in the uterus, it is not commonly known
whether RANKL is localised to the stromal cells along with PR or whether it
remains an epithelial target. The data in figure 3.24 shows that there is a
significant increase in wild-type expression of RANKL when treated with
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progesterone for six hours, (**;p<0.05) so whilst it is not as significant as some
of the other results, there is still a definitive upregulation occurring upon
treatment. The comparisons made between the other genotype samples which
were treated with progesterone for six hours lack any statistical significance and
therefore reveal very little about how RANKL may be functioning in the uterus
during the periimplantation period or how its activity is being regulated.

Mig6:
Previous studies have shown that animals with disruption of Mig6 by gene
targeting develop epithelial hyperplasia thus implying that Mig6 is a potential
tumour-suppressor gene (Zhang YW et al, 2007). Mig6 interacts with the EGFR
family of receptors and negatively regulates EGF signalling thereby providing
through negative feedback a fine tuning of EGF signalling shortly after its
activation (Zhang et al, 2006). It has been suggested that Mig6 may provide a
checkpoint for normal cell proliferation in certain tissues (Zhang et al, 2007); it
is quite possible that this statement applies to the uterus.
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M ig6 m RNA
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Mig6 mRNA expression in the uterus of Wild-Type mice and
mice with varying PR genotypes that have been either control
treated or treated with P alone for 6 hours
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Fig 3.25: qPCR analysis of Mig6 mRNA expression in the uterus of wild-type mice, PRAKO,
PRBKO, PRKO mice that have either been treated with control or treated with progesterone for six
hours. Gene expression is analysed in terms of fold induction relative to the wild-type control and error
is assessed by standard deviation. A paired Student’s t-test was used to analyse the data for statistical
significance. Mig6 shows strong upregulation in the uterus when the wild-type samples are treated
with progesterone for six hours (*;p<0.01). The other significant difference which occurs in Mig6
expression occurs with its downregulation in the PRKO samples when compared to its expression in
the wild-type P-treated samples (p<0.01) – this suggests that Mig6 is regulated by progesterone in the
uterus. There is no regulation of Mig6 of any statistical significance with regards to the specific PR
isoforms; PR-A or PR-B.

Mig6 mRNA expression may be upregulated in a precautionary manner during
the proliferative periimplantation period to curb any aberrant growth within the
uterus. Mig6 mRNA expression in the wild-type samples after six hours of
progesterone treatment is clearly upregulated by 4-fold when compared to the
wild-type control treated samples, this upregulation of Mig6 upon treatment is
deemed to be statistically significant. In addition, Mig6 expression falls
drastically in the P-treated samples where PR has been specifically ablated; this
infers that Mig6 is subject to progesterone regulation within the uterus. Again
this downregulation of Mig6 in the PRKO sample is statistically significant as p
< 0.01. With regards to the PR isoforms, PR-A appears to exert most influence
over the expression of Mig6 but there does seem to be some redundant
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regulation by PR-B in the absence of PR-A. It could be possible that Mig6 is
regulated by a PR A:B heterodimer
.

3.3.(v) The Non-Comparative Uterus Target Genes:
Indian Hedgehog:
The qPCR data obtained for Indian hedgehog in figure 3.24 was analysed using
the student’s t-test to assess the statistical significance of the results obtained.
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Fig 3.26: qPCR analysis of Indian Hedgehog expression in the uterus of wild-type mice, PRAKO, PRBKO,
PRKO mice that have either been treated with control or treated with progesterone for six hours. Gene
expression is analysed in terms of fold induction relative to the wild-type control and error is assessed by
standard deviation. A student’s t-test was used to analyse the data for statistical significance and produced
several significant results for this data set. Indian hedgehog expression increases in the wild-type samples
once they are subjected to six hours of progesterone treatment. Indian hedgehog also shows regulation by
progesterone in the P-treated samples. Indian hedgehog is significantly in the PRKO sample when PR is
totally ablated but also when the PR-A isoform is ablated thus suggesting that Indian hedgehog is regulated
by progesterone; in particular PR-A.

After exposure to progesterone for six hours, the expression of Indian hedgehog
in the wild-type P-treated samples increased significantly when compared to the
expression levels observed in the wild-type control samples. Indian hedgehog
has been identified as an important mediator of progesterone action in the uterus
and figure 3.26 does confirm its regulation by progesterone in the P-treated
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samples. This is demonstrated by comparing the expression of Indian hedgehog
in the wild-type P-treated samples to firstly the PRKO sample where there is a
total knockout of PR, and then comparing the wild-type expression to the
PRAKO sample where there is a partial ablation of PR function. The results
show significant downregulation of Indian hedgehog in both these samples
which infers that Indian hedgehog mRNA expression is positively regulated by
PR and in particular PR-A. Whilst PR-A appears to be the predominant isoform
with regards to Indian hedgehog regulation in the uterus, fig 3.26 suggests that
PR-B does act to induce some upregulation when PR-A is knocked out.

BMP2:
Studies have shown that in human endometrial stromal cells, addition of BMP2
to the hormone regime enhanced the in vitro decidualisation process whereas
siRNA to BMP2 prevented decidualisation in vitro (Franco et al, 2008).

Fold Induction of
BMP2 mRNA
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Fig 3.27: qPCR analysis of BMP2 expression in the uterus of wild-type mice, PRAKO, PRBKO, PRKO mice
that have either been treated with control or treated with progesterone for six hours. Gene expression is
analysed in terms of fold induction relative to the wild-type control and error is assessed by standard
deviation. BMP2 is downregulated in the wild-type samples after treatment with progesterone for six hours.
Statistics showed that the decrease in BMP2 after treatment is not as significant as other previous results as it
is only deemed significant when **; p< 0.05. BMP2 shows more significance with regards to the P-treated
samples, a comparison of BMP2 expression in the wild-type and the PRKO treated samples indicate BMP2 is
regulated by progesterone as its expression is downregulated in the P-treated samples once PR is ablated
(p<0.01). No statistical data of any significance could be reported for the specific PR isoforms.
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The data set produced by the qPCR analysis of BMP2 expression in the uterus
produced some unexpected results. BMP2 is known to have an important role in
the decidualisation process therefore it would be expected that its expression
would increase during the periimplantation period whereas the results from
figure 3.27 clearly show a significant downregulation of the gene in the wildtype samples following the six hour treatment of progesterone. BMP2 does
however exhibit progesterone regulation with regards to the PRKO samples as it
is significantly downregulated in the P-treated samples in absence of PR.
Unfortunately, figure 3.27 could not provide any statistically significant results
as to how BMP2 is being regulated by PR or which isoform is the dominant
receptor, there could of course be heterodimeric regulation of both PR-A and
PR-B but again this cannot be conclusively determined on the basis of figure
3.27’s results.

Hoxa10:
Analysis of Hoxa10 mRNA, in figure 3.28, produced a similar uterine
expression pattern to that of Indian hedgehog. Statistical analysis does show that
HoxA10 increases significantly in the wild-type samples following the
prescribed treatment of progesterone for six hours (p<0.01). Hoxa10 is
downregulated in the P-treated PRKO samples when PR is totally ablated, it is
also downregulated in the absence of the PR-A isoform in the PRAKO sample
suggesting that any of the positive regulatory effects of progesterone on
HoxA10 are mediated through the PR-A isoform. Whilst some mRNA induction
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was observed in the PRBKO samples, the large error bar meant that no
statistically significant comparisons could be made with the P-treated samples.

Fold Induction of
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Fig 3.28: qPCR analysis of Hoxa10 expression in the uterus of wild-type mice, PRAKO, PRBKO, PRKO
mice that have either been treated with control or treated with progesterone for six hours. Gene expression is
analysed in terms of fold induction relative to the wild-type control and error is assessed by standard
deviation. A paired Student’s t-test was used to analyse the qPCR results in terms of statistical significance.
There is significant upregulation of HoxA10 in wild-type samples which have been treated with progesterone
for six hours as opposed to those which have been control treated (*;p<0.01). HoxA10 also shows regulation
by progesterone as it is significantly downregulated in the P-treated PRKO samples and also in the P-treated
PRAKO samples. Both decreases are considered to be statistically significant when compared to the
expression profile of HoxA10 in the wild-type P-treated samples (p,0.01).
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4. Discussion
Progesterone is a very powerful ovarian steroid hormone and its central role in
female fertility has been well established since the early half of the 20th century
however the definitive mechanisms of action by which progesterone functions
remain elusive despite many years of research in this area. Our lab, along with
many other labs, has focused its time, resources and efforts on progesterone
investigations to try and decipher the specific signalling pathways of
progesterone within the various reproductive tissues. The ultimate goal of these
many and varied investigations is to generate a clear and concise account of
how progesterone mediates its actions at a molecular level and whether there are
common threads governing how it mediates its specific actions in the different
target tissues.

4.1. qPCR Analysis of the Microarray Target
Genes:
This work focuses on how progesterone mediates its effects in pregnancyassociated mammary gland development therefore a critical part of the project
was to simulate a pregnant environment of intense growth and active
proliferation within the mammary gland. A three week course of treatment
consisting of low doses of estrogen and progesterone produced this desired
effect within the mouse as it was equivalent to day 12.5 of the murine
pregnancy. It was thought that this would be an optimum time point for the
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activity of many of the proliferative target genes governing ductal branching
and alveolar differentiation that our lab wanted to look at in the mammary
gland. Any directly regulated target genes should exhibit very strong and clear
expression profiles with regards to the wild-type and PRKO samples after
receiving the three week course of treatment. The second reason for using threeweek E&P treatment stems from the observation that the protective effects of an
early first pregnancy observed in humans is mimicked with this form of
treatment in rodents. Therefore results obtained from analysis at this time point
may be more indicative of a protected, healthy, normal mammary gland
environment which could be useful if a comparative analysis was to be made in
a tumourigenic model at a later stage.
The purpose of the first study was simply to continue the investigative efforts of
a previously performed microarray. The microarray was an effective strategy in
identifying the full spectrum of target genes of mammary PR during pregnancy.
The microarray provided a mammary transcriptome that was generated by
progesterone exposure and which contains a vast amount of information about
the genetic network that comprises and established the developed mammary
gland. The target genes that were looked at in this represent only a small
percentage of the parallel and interconnected signalling cascades required for
normal, healthy mammary gland development, many of them need to be further
investigated to map out their individual pathway.
The data obtained from the microarray outlined a number of genes which
showed strong regulation by progesterone; these genes were further analysed
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using new mouse models and quantitative PCR technology. Amphiregulin,
Wnt4 and RANKL were all well known proliferative genes which have a
history of mammary gland expression therefore our lab thought it would be
worthwhile to assess their expression during a simulated pregnant state and
determine their activity with regards to that particular environment. RANKL
(Fig3.5) and Amphiregulin (Fig3.7) showed stronger regulation by progesterone
than Wnt4 (Fig3.6) and their transcriptional response to the administered
treatment was also more pronounced and sensitive than that seen in Wnt4.
RANKL exhibited a 12-fold induction in mRNA expression in the wild-type
sample following treatment with E&P (Fig3.5) whilst Amphiregulin mRNA
expression also increased by 13-fold in the wild-type E&P-treated samples
(Fig3.7). Both target genes also demonstrated significant downregulation in the
absence of PR. RANKL appears to play a significant role in the later stages of
pregnancy. It is suggested that the proper development of the lobuloalveolar
structures requires an initial wave of proliferation signalled via RANKL that
allows expansion of the alveolar bud epithelium followed by a decrease in the
RANKL signal which is critical for the lobuloalveolar structures to differentiate
to highly vacuolated and secretory alveoli (Gonzales-Suarez et al, 2007). At
12.5 days into a murine pregnancy, the mammary gland is preparing for
lactation and alveolar development would be largely underway thus high levels
of RANKL mRNA seen in figure 3.5 would correlate well with the expected
observation. It would have been of interest to quantify RANKL mRNA
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expression at a later time point to determine if its expression levels did drop off
to accommodate the differentiation of the alveolar lobules.
Although Amphiregulin demonstrates regulation by P in both the microarray
and in the subsequent qPCR analysis (Fig 3.7), current literature (Sternlicht et
al, 2008, McBryan et al, 2008) regards it as a regulator of estrogen-induced
proliferation since Amphiregulin is mostly known as a mediator of ductal
branching in puberty rather than pregnancy. Pregnancy is recognised as a period
of increased ductal branching and outgrowth therefore an important mediator of
branching such as Amphiregulin would be expected to be involved. In puberty,
the proposed mechanism of action of Amphiregulin in breast epithelial cell
proliferation is that ER-positive cells, in response to stimulation by estrogen,
secrete paracrine factors such as Amphiregulin which then act indirectly to
stimulate neighbouring ER-negative cells (McBryan et al, 2008). Active
Amphiregulin then binds to EGFR in the stroma of the mammary gland. This
induces proliferation of nearby epithelial cells, by a possible paracrine
mechanism, resulting in ductal outgrowth. This paracrine mechanism of
signalling is identical to that of PR therefore it is possible that Amphiregulin can
be regulated by both ovarian steroid receptors but at different stages of
development (McBryan et al, 2008). It is also possible that the 13-fold induction
of Amphiregulin in figure 3.7 could be the result of strong synergy between ER
and PR during pregnancy. There is also evidence that Amphiregulin expression
is reduced in prolactin receptor knockout mice, indicating that Amphiregulin
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might also be regulated by prolactin in mammary epithelial cells during
pregnancy (McBryan et al, 2008).
qPCR analysis of Wnt4 mRNA expression produced less regulation by P than
RANKL or Wnt4. Figure 3.6 demonstrates negligible induction in the wild-type
samples following three week E&P treatment however Wnt4 expression is
significantly downregulated in the PRKO samples thus confirming its status as a
target of progesterone regulation in the mammary gland. Wnt4 is a secreted
paracrine mediator which is active in early pregnancy (Oakes et al, 2006)
therefore 12.5 days of pregnancy could be due to too late a time point to observe
a strong induction. Wnt proteins regulate a wide range of proliferative cellular
processes and it is likely that there is more than one Wnt signalling pathway
functioning in the mammary gland thus it is possible that Wnt4 is not a direct
target of PR and may mediate its effects further downstream than RANKL or
Amphiregulin (Sternlicht et al, 2006).
In a recent paper by Fernandez-Valdivia, 2008, Wnt4, RANKL and
Amphiregulin was analysed in the murine mammary gland and the genes were
found to be transcriptionally induced by acute exposure to progesterone (within
76 hours) in the mammary gland of ovariectomised mice. It would have been
advantageous to the analysis of these genes if this study had incorporated
various time points of treatment to monitor the expression profiles as the
mammary gland progresses through pregnancy. Inclusion of such data would
give a better indication of where in pregnancy-associated development each
gene is most potent in its effects. A better characterisation of each gene in these
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terms may aid in understanding the signalling mechanisms that are in place
during this proliferative and differentiating time.
Elf5 was also downregulated in the microarray following E&P treatment in
PRKO mice. Elf5 was of particular interest as it is commonly associated with
prolactin signalling however the results obtained in this study did produce a
strong progesterone-regulated profile for Elf5 (Fig 3.8). Elf5 mRNA expression
did increase by 8-fold upon treatment with E&P for three weeks (p<0.01) and it
did decrease to wild-type control-treated levels in the absence of PR (p<0.01).
However, Elf5 is always referred to as a prolactin target gene rather than a
progesterone target gene thus these results could be indicative of convergence or
redundancy between these two hormonal pathways in a pregnant mammary
gland that is preparing for lactation. Recent literature states that ERα, PR and
PrlR may be colocalised to the same ductal luminal cells (LaMarca, 2008). If
progesterone and prolactin are in such tight proximity to one another, it is
possible that there may be some overlap and compensation in play.
It was important that the microarray study should also include genes that have to
be downregulated in order to accommodate the proliferation and differentiation
which is so synonymous with pregnancy-associated mammary gland
development. They also require regulation by progesterone that is just as
essential as that incurred by the proliferative markers and their inclusion in the
study emphasised that.
Administration of exogenous TGF- β1 into actively branching mouse mammary
glands using slow-release pellets resulted in reversible growth inhibition and
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involution of mammary gland end buds (Gorska et al, 1998). It is suggested that
TGF-β1 is a negatively regulated progesterone target gene yet it could still be an
important mediator of progesterone action in the mammary gland (Monks et al,
2007). TGF-β1 production and activity are differentially regulated during
mammary gland development such that periods of proliferation were
accompanied by decreased TGF-β1 activation in most cells (Ewan et al, 2005).
TGF-β1 is highest in the virgin and early pregnant gland, when PR levels are
lowest or only beginning to rise. TGF-β1 expression falls during mid-pregnancy
and remains low until involution (Monks et al, 2007). Figure 3.9 concurs with
the downregulation of TGF- β1 at 12.5 days of pregnancy in the mouse model
as its expression is decreased by half in the EP treated wild-type mice compared
to the control-treated wild-type mice. Once PR is ablated, TGF- β1 mRNA
expression returns to wild-type control treated levels. Progesterone seems to be
suppressing the inhibitory effects of TGF-β1 during pregnancy so that the
mammary gland can proliferate and develop to prepare for lactation.
TGF β2 was analysed for its anti-proliferative effects in the mammary gland
because of its associations with TGF- β1. It is not a well established mammogen
but its expression is known to increase during pregnancy and it is localised to
the epithelial ducts and the alveoli. The qPCR analysis of TGF-β2 showed no
significant regulation in the wild-type mouse following the three weeks of E&P
treatment and no regulation by PR was observed. However, TGF- β2 is regarded
as a marker of late pregnancy and it is expected to increase linearly to day 17 of
pregnancy therefore it is impossible to tell from the data (Fig 3.10) whether
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TGF-β2 would continue to increase if treatment was prolonged or whether
figure 3.10. represents the maximum induction of TGF-β2 under such
conditions. Again, analysis at various time points of treatment would have
offered a better insight into TGF-β2s expression during pregnancy.

Mig6 is a gene which appeared in the microarray and exhibited negative
regulation by PR. Most of the Mig6 literature focuses on the liver, the skin or
the lungs, however in terms of the mammary gland; Mig6 is hypothesised to
have an anti-proliferative effect. Mig6’s role as an inhibitor of the EGFR
signalling pathway coupled with its potential as a tumour suppressor made it an
important candidate gene for negative regulation in terms of progesterone and
pregnancy associated mammary gland development. Sfrp2 is another antiproliferative factor capable of inhibiting the effects of progesterone during
pregnancy as it inhibits the Wnt signalling pathway. qPCR analysis of both
genes after three weeks of E&P treatment produced very similar expression
profiles (Fig 3.11 and 3.12). Both genes increased in the wild-type samples
following treatment and the increase in each was ~2-fold. Neither gene
demonstrated any regulation by PR when analysed in the PRKO sample
therefore it is unlikely that Mig6 or Sfrp2 are directly regulated by PR at this
time point. The analysis of the two genes at the earlier time point of 48 hours to
determine whether they exhibited an early transcriptional regulatory response to
progesterone produced a differing expression profile to that seen at three weeks
(Fig 3.13 and 3.14). The results at 48 hours, suggests that Mig6 and Sfrp2 did
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have an early yet strong transcriptional response to the hormonal surge of the
simulated pregnant state.
Consideration of the opposing regulatory profiles produced at the two separate
time points enables the data presented in figure 3.11 and 3.12. to be better
explained. It is hypothesised that progesterone may exert a strong and
significant effect on Mig6 and Sfrp2 and downregulate their expression early on
in pregnancy in order to curb any anti proliferative effects they may have on the
initial proliferative processes within the mammary gland (Fig 3.13, 3.14). The
effects of progesterone on these anti-proliferative genes are then reduced as
pregnancy progresses and the proliferation has become more established and
stable. At this stage the anti proliferative effects may be considered negligible
and so their expression may rise without threat to the structure of the mammary
gland (Fig 3,11, 3,12).

4.2. The BDNF Study: A Novel Target of
Progesterone Signalling in Pregnancy-Associated
Mammary Gland Development
The second of the three studies in this project revolved around the neuronal
gene; brain derived neurotrophic factor (BDNF) which was a novel target gene
in terms of mammary gland development. This study was more exploratory as
there was no published literary findings with regards to any role BDNF may
have had in the mammary gland or in general mammalian reproduction. There
are overlapping features between this study and the first study, as BDNF first
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came to the attention of our lab because of the regulation with regards to
progesterone it demonstrated in the microarray. Our lab was genuinely intrigued
by the BDNF results and thought that it would be of interest to further pursue it
as a novel target of progesterone regulation in pregnancy-associated mammary
gland development. BDNF is a secreted protein, which belongs to a class of
growth factors, that are capable of signaling particular cells to survive,
differentiate, or grow therefore it was thought it may replicate this in some form
if active in the developing mammary gland. On the basis of the microarray data
(Fig 1.10) and other data (Fig 3.15), the decision was made to generate
conditional BDNF knock-out mouse models to investigate the phenotype
produced in its absence so that a hypothesis could be formed as to where in the
mammary gland BDNF was having an effect.
The BDNF mouse models and the other mouse models included in this cohort
also received the three week E&P treatment because as with the first study,
pregnancy-related activity was also the principle interest for BDNF
investigations. Hyperbranching was rampant in the BDNF knockout mammary
gland (Fig 1.17A) therefore it was hypothesised that BDNFs function was to
curb or limit the proliferative signals which are enforced during pregnancy.
Analysis was carried out on the three major proliferative signals which
demonstrated mRNA regulation by progesterone in the microarray (Fig 1.10).
RANKL, Amphiregulin and Wnt4 were all analysed in conditional BDNF
heterozygous knockout models and in conditional BDNF homozygous
knockouts to determine whether they were regulated by BDNF. The three genes
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demonstrated very similar transcriptional responses in the BDNF knockout
models. RANKL (Fig 3.18A) and Amphiregulin (Fig3.18B) once again undergo
significant upregulation in the wild-type samples when treated with E&P for
three weeks, this upregulation is then maintained in the partial or complete
ablation of BDNF. Wnt4 mRNA expression does not increase to the same extent
as RANKL and Amphiregulin following the hormonal treatment (Fig 3.18C)
however the upregulation that does occur is also maintained in the two BDNF
knockout models. As mentioned, the phenotypic consequences of BDNF
ablation is hyperbranching and whilst the three genes retained their proliferative
profiles in the absence of BDNF, there was no increase of mRNA expression in
any of the three. It, therefore must be considered that if the hypothesis was to
hold true, then mRNA expression of the proliferative mediators should actually
increase if BDNF is not there to curb their effects. This was not evident from
the qPCR data in figure 3.18 therefore it could be possible that BDNF is just
one factor of many that might be working cooperatively to negatively regulate
the proliferative mediators in pregnancy-associated mammary gland
development. It might also be necessary to analyse other potential markers of
proliferation as opposed to the proliferative signals themselves. Some cell cycle
markers of proliferation may indicate the expected increase in proliferation
when BDNF is ablated in a faster and more efficient manner.
BDNF mRNA expression was analysed in wild-type samples which had been
differentially treated to determine whether BDNF exhibited an early
transcriptional response to hormonal stimuli. The resultant data set (Fig 3.19)
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did not produce any significant analysis. BDNF mRNA expression did appear to
increase but there was large error bar present on the wild-type E&P-treated
samples because of the animal-animal variation in that particular cohort. BDNF
has been shown to have a PRE present in its genome hence it should be directly
regulated by progesterone however the P-treated wild-type sample in Fig 3.19
showed very little upregulation after 48 hours. The data thus infers that BDNF
does not have an early transcriptional response to progesterone but that there
may be some synergy between estrogen and progesterone that can increase its
expression. PR is a transcriptional target of ER therefore maybe together
estrogen and progesterone create a more potent regulatory force than
progesterone alone can after only 48 hours.
Using qPCR analysis in this study failed to produce any definitive results with
regards to BDNF function in the mammary gland. The use of PRKO and PR
isoform conditional knockout models would have enhanced the BDNF data set
(Fig 3.19) enormously. Initial data produced by the lab incorporated PR-A and
PR-B knockout models and observed that PR-A is the dominant isoform in the
progesterone mediated regulation of BDNF. A staggered treatment time would
also be of interest in elucidating how and when BDNF is being transcribed with
regards to progesterone.
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4.3. Progesterone Regulated Target Genes of the
Uterus
The uterus was of particular interest with regards to progesterone signalling due
to the contrasting effects it elicits in both tissues. Progesterone has proliferative
effects in the mammary gland but in the uterus, it appears to be antiproliferative as it counteracts the proliferative effects of estrogen hence why
progestins are administered in conjunction with estrogen for menopausal
women on HRT.
The mouse models used for the uterine investigations were treated with
progesterone alone for six hours as this was thought to mimic the priming effect
that progesterone has on the endometrium during the periimplantation period.
Exposure to progesterone at this early stage is essential for the decidualisation
reaction which allows embryo implantation to occur successfully.
The three proliferative target genes, RANKL, Amphiregulin and Wnt4 are
revisited again in this study and it is on the basis of their expression profiles that
comparisons can made between the uterus and the mammary gland. A huge
advantage in the analysis of the uterus genes is the inclusion of the PR-isoform
knockout samples; PRAKO and PRBKO. Using these knockout models give a
more specified regulatory profile for each target gene and generally improves
the quality of the data obtained from the qPCR.
Amphiregulin displays its strongest regulation by PR in the uterus with a 150fold induction of mRNA expression after only six hours of progesterone
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treatment. Such a powerful response at such an early time point is quite unusual
and infers that Amphiregulin is a direct target of P signalling and has an
important role to play in the uterine implantation process. Byun et al, 2008
examined the uterine expressions of the epidermal growth factor (EGF) family
to elucidate their exact role in rat pregnancy. EGF and its receptors' (EGF-R)
mRNA levels increased significantly at implantation after which their
expression gradually decreased. Amphiregulin was strongly expressed around
implantation and also at mid-pregnancy. Treatment of pregnant rats with the
progesterone antagonist; RU486, at gestational day 5 blocked the expression of
all the EGF genes including Amphiregulin, and administration of immature rats
with progesterone induced the uterine expression of all the genes. The major
role of Amphiregulin is cell proliferation (McBryan et al, 2008) thus it makes
sense that it would be so strongly upregulated during the periimplantation
period as that is a time of intense cell growth to thicken the uterine wall in
preparation for receiving the blastocyst. As well as the cellular growth that is
involved in the decidualisation reaction, there is also a huge amount of cellular
differentiation occurring, which Amphiregulin could also be involved in. The
PR isoforms in figure 3.22 infer that PR-A is the dominating regulator of
Amphiregulin mRNA expression however since neither PR-A or PR-B can
upregulate Amphiregulin to the same degree as the wild-type sample, there may
be some synergy between the two to effectively stimulate Amphiregulin’s
expression. The highly proliferative effects mediated by Amphiregulin stand in
stark contrast to the progesterone’s anti-proliferative action in the uterus. It
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seems that in the case of pregnancy-related regulation in the uterus,
progesterone is required to prime the cells of the endometrium so that they are
prepared for implantation. It seems that this priming action requires
progesterone to promote growth, proliferation and differentiation therefore
demonstrating how it can mediate its signalling pathways very eloquently to
accommodate the differing and immediate requirements of the specific tissue in
which it is functioning.
Wnt4 and RANKL were also analysed in the uterus but their fold inductions
were not as high as Amphiregulin are not as definitive as those induced in the
mammary glands. Wnt4 shows only a slight increase in its wild-type mRNA
expression following the six hour treatment. The data derived from the PRAKO
samples suggests that the PR-B isoform may be increasing Wnt4 mRNA
expression, even more so than the wild-type P-treated sample which may infer
an inhibitory role for PR-A in Wnt4 signalling in the uterus (Fig 3.23). Despite
the lack of clear regulation seen here, Wnt4 is still established as an important
mediator of the decidualisation reaction. It is most likely that Wnt4 is not a
direct target of PR in the uterus and that it lies too far downstream to display an
acute response to progesterone regulation. qPCR data for RANKL mRNA
expression did not elicit any significant results. Unlike in the mammary gland,
RANKL does not appear to have a very important role in the uterus at this
particular time point. Thus in conclusion, only one out of the three proliferative
mediators of progesterone; Amphiregulin, came close to replicating its effects in
both the uterus and the mammary gland (Fig 3.7 and Fig 3.22).
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Mig6’s role as a mammary anti-proliferate made it an important choice for the
uterine comparison to determine whether it was regulated in the same manner in
both tissues. Mig6 was the only anti-proliferative target gene examined in both
the mammary gland and the uterus because of the inhibitory effect that it has
upon the EGFR and its signalling pathway. It may be of interest to determine
the Mig6 mRNA expression profile in the uterus so as to contrast it to the
mRNA expression profile which was so strongly induced by Amphiregulin; a
major ligand of the EGFR. Mig6 does exhibit a significant and acute response to
the six hour progesterone-treatment with a 4-fold increase in its mRNA levels.
The PR-A isoform appears to be the more dominant isoform receptor and there
is also significant downregulation of Mig6 in the absence of PR (Fig 3.25). The
qPCR analysis infers that Mig6 is induced in the uterus at the same time as
Amphiregulin and both appear strongly regulated by progesterone. It may be
possible that PR is able to upregulate the proliferative factor Amphiregulin
whilst at the same time upregulate its indirect inhibitor in an attempt to control
the proliferation. This is a similar hypothesis to that proposed for the BDNF
action in the mammary gland.
This study relied heavily on literary findings therefore other previously
researched progesterone-regulated signalling pathways were explored which
were not directly relevant to the mammary gland yet were still informative with
regards to the differential action of progesterone in various tissues.
Indian hedgehog is one of these genes, it is expressed in the luminal and
glandular epithelium of the uterus and its expression profile peaks before the
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implantation of the blastocyst occurs and then decreases almost immediately
after. The PR-Cre/lox-Ihh knockout points to Ihh as a major affector of PR
action in the uterus since its phenotype mimics that of the PRKO mouse (Franco
et al, 2008). Indian hedgehog is upregulated after treatment with P in the wildtype mice (Fig 3.26) which further confirms its acute response prior to
implantation.
Bone morphogenic protein 2 (BMP2) is localised to the stromal cells in the
endometrium and has an important role to play in the decidualisation reaction.
qPCR analysis of BMP2 mRNA expression failed to display any significant
regulation. BMP2 expression decreased upon treatment with P in the wild-type
samples but did show regulation by PR with the PRKO samples (Fig 3.27). The
literature states that BMP2 is a downstream effector of COUP-TFII which is a
known target gene of Indian hedgehog signalling. Just like Wnt4, BMP2 may be
too far downstream of PR following six hours of treatment to show any rapid
induction; its expression may continue to rise beyond the time limitations
imposed by this study.
The final target analysed for the uterus was HoxA10. Hoxa10 is a transcription
factor thought to have a role in cell proliferation during the decidualisation
reaction and also a mediator of prostaglandin signalling in response to PR (Lim
et al, 1999).
HoxA10 mRNA expression does increase 1-fold following treatment of wildtype mice with progesterone for six hours. There is strong literary support for
Hoxa10 as an important mediator of P action in the uterus but the initial data
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obtained from the uteri samples in this study does seem to reflect this evidence
for Hoxa10 as a critical target of progesterone regulation in the uterus.

4.4. Future Works:
The use of the 48 hour data, whilst limited due to the lack of a PRKO model,
was nevertheless helpful in terms of analysis of the microarray target genes.
Three weeks of E&P treatment did provide the required proliferative
environment but it would have been hugely advantageous to this study to have
had shorter concurrent treatment time points so that more of the genes could be
investigated as direct effectors of progesterone signalling. The proliferation
within the mammary gland after three weeks is quite intense and many
pathways may be already activated which makes the sequence of such pathways
increasingly difficult to decipher. Immunostaining for the localisation of the
target genes and PR would be an advantage for further investigations into the
paracrine signalling mechanisms of PR. Protein analysis for some of the genes
may also have been valuable to discerning gene activity during the simulated
pregnancy, this could have been performed using Western blotting techniques.
With regards to the BDNF study, it is my opinion that for the pioneer
investigations of novel targets, it would be easier to carry out initial studies on
mammary cell lines rather than mouse models. Cell culture would allow more
experiments to be done on conditional BDNF knockouts in larger numbers, in a
more timely fashion and at less cost to the lab. Larger data sets would also
eliminate the problem of animal-animal variability that is often associated with
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the smaller sample sizes. When more information has been gathered on a novel
target using cell lines, animal models could then be used more efficiently and
effectively to enhance and continue previous investigations. Using ChIP
analysis would also be of interest to determine if the PR homodimer is binding
directly to the BDNF promoter sequence which would thus further confirm
BDNF as a direct target of PR.
The final study of the uterus was able to instigate a screening of potential target
genes which would be active in the uterus during decidualisation. Although this
study was able to use specific PR-isoform knockout models, no target gene was
singled out for further analysis to discover where in the signalling pathway it
was positioned. It would be a significant advantage for this study to follow
through on some of the results and perhaps monitor their mRNA expression at
numerous time points to gauge their progesterone regulatory expression as the
uterus develops past the decidualisation reaction.
A study on the ovary would also be important to assess how PR controls
progesterone signalling on a third reproductive tissue to try and better
understand the differential regulatory powers of progesterone and how it adapts
its signalling pathways to suit the specific environment.
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5: Conclusion:
As previously mentioned, the fundamental concept driving these experiments is
how endeavours to better understand normal mammary branching
morphogenesis are essential to explaining the abnormal; in the case of the
mammary gland to determine how and where progesterone-regulated signalling
pathways may become vulnerable to corruption which may induce tumour
formation and malignancy. This concept is of greater significance in the
mammary gland because a normal healthy mammary gland progresses through
the same general principles, from proliferation to invasion, which are also seen
to occur in malignant disease.
The purpose of these studies was the elucidation of progesterone-regulated
target genes. The studies have looked at many such genes in differing treatment
scenarios as well as differing tissue environments. This project has provided a
deeper insight into the regulation of each gene on an individual basis when
subjected to either a pregnant state or in the case of the uterus a periimplantation
state. These genes were analysed at two critical times of reproduction and the
responses they elicited may be useful for future research to decipher the
inherent pathways upon which they operate. For example; Amphiregulin, Wnt4
and RANKL were hailed as major proliferative signals throughout this project
and were grouped together beneath this umbrella term, however the work that
was carried out on them highlighted that there were significant differences
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between them especially with regards to how and where they were susceptible
to progesterone regulation.
In conclusion, the importance of progesterone and PR to mammary gland
development has been proven many times over yet much work remains to be
done so that a molecular context can be applied to the activity and consequences
of PR action in the developing mammary gland. Whilst this project has
introduced many genes that might be important in establishing such sought-after
signalling pathways, it has still only offered an introduction to the possibilities
that they represent for progesterone-related molecular research thus more
techniques and resources need to be employed to uncover the numerous
molecular mechanisms in play within the reproductive tissues.
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6. Appendix
Protocol for preparation of DEPC water for RNA extraction:
•

This protocol for DEPC water used 0.2mls of DEPC per 100mls of water
DEPC = Diethylpyrocarbonate

•

A 500ml glass bottle was filled with 400mls of double distilled water
using a 500ml graduated cylinder – room was left in the bottle as the
volume may expand during autoclaving

•

In a fume hood, 800µl of DEPC was added to the 400mls of double
distilled water

•

The bottle was shaken vigorously to ensure that the DEPC went into
solution

•

The bottle was then left overnight at room temperature

•

The bottle was then autoclaved for 15 minutes

Protocol for preparation of 75% ethanol with DEPC
•

This solution is to be made fresh for each RNA extraction, for this
experiment a 100ml solution was made up

•

In the fume hood, 75mls of 100% ethanol was measured using a 100ml
graduated cylinder

•

25mls of DEPC water was then added to the graduated cylinder

•

The solution was then transferred to a glass bottle and was thoroughly
shaken

•

The 75% DEPC ethanol was then stored in a fume hood until ready for
use

•

The glass bottle was clearly marked ‘RNA use only’ and was sprayed
with RNaseZap
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Protocol for preparation of a sample denaturing buffer i.e.
orange buffer
•

The solution preparation was carried out in a fume hood
•

10X denaturing buffer

720µl

•

98% formamide

3600µl

•

37% formaldehyde

1170µl

•

Ethidium bromide (10µg/µl)

24µl

•

Double distilled water

490µl

•

The above mix was then filter sterilised into a clean fresh 15ml Falcon
tube

•

The buffer was then stored at -20ºC, the solution however does not
freeze

Protocol for preparation of RNA loading buffer

•

•

80% (v/v) formamide

•

1mM EDTA pH8.0

•

0.1% (w/v) bromophenol blue

•

0.1% (w/v) xylene cyanol

The loading buffer was made up in a 0.5ml RNase free eppendorf tube
and stored at 4ºC
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